{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## üìö Prerequisites\n",
    "\n",
    "Before running this notebook, ensure you have provisioned your Azure resources, configured your environment variables (Search endpoint, key, and index name), and set up a Conda environment to manage dependencies. Refer to [REQUIREMENTS.md](REQUIREMENTS.md) for full setup instructions.\n",
    "\n",
    "## üìã Table of Contents\n",
    "\n",
    "This notebook walks through **two approaches for indexing policy documents stored in Azure Blob Storage**, using either the **Push SDK** or the **native Azure AI Search Indexer**.\n",
    "\n",
    "#### 1. [**Indexing Policy Documents from Blob Storage Using the SDK (Push Model)**](#index-using-push-sdk)\n",
    "\n",
    "In this approach, we build a fully controlled indexing pipeline using the Azure SDK for Python.\n",
    "\n",
    "You will learn how to:\n",
    "\n",
    "- Load PDF or text-based policy documents directly from Blob Storage\n",
    "- Preprocess and chunk content for retrieval\n",
    "- Generate embeddings using Azure OpenAI\n",
    "- Upload documents, metadata, and vector embeddings into Azure AI Search using the `SearchClient`\n",
    "\n",
    "This method gives you **maximum flexibility** and is ideal when you need to integrate your own preprocessing logic, custom chunking strategies, or real-time updates.\n",
    "\n",
    "#### 2. [**Indexing Policy Documents Using Azure AI Search Indexers with Custom Skillsets**](#index-using-indexer)\n",
    "\n",
    "This approach uses the built-in **Azure Search Indexer** to automatically crawl documents from Blob Storage and enrich them using a **custom skillset**.\n",
    "\n",
    "You will learn how to:\n",
    "\n",
    "- Connect Blob Storage as a data source\n",
    "- Define a skillset that performs OCR, embedding, or text extraction\n",
    "- Automatically map enriched fields into your Azure Search index\n",
    "\n",
    "This method is best when you want to **automate the ingestion pipeline** with minimal custom code, leveraging Azure's low-code enrichment platform.\n",
    "\n",
    "> By the end of this notebook, you‚Äôll understand how to build both a **fully customized ingestion flow** using the SDK and a **scalable low-code pipeline** using native indexers with skillsets ‚Äî both optimized for retrieving policy content stored in Blob Storage.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Directory changed to c:\\Users\\pablosal\\Desktop\\aihlsignited-medindexer\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "from tenacity import retry, wait_random_exponential, stop_after_attempt\n",
    "from dotenv import load_dotenv\n",
    "import os\n",
    "import json\n",
    "import copy\n",
    "from azure.core.credentials import AzureKeyCredential\n",
    "from azure.search.documents import SearchClient\n",
    "from azure.search.documents.indexes import SearchIndexClient\n",
    "from azure.search.documents.indexes.models import (\n",
    "    ExhaustiveKnnAlgorithmConfiguration,\n",
    "    ExhaustiveKnnParameters,\n",
    "    SearchIndex,\n",
    "    SearchField,\n",
    "    SearchFieldDataType,\n",
    "    SimpleField,\n",
    "    SearchableField,\n",
    "    SearchIndex,\n",
    "    SemanticConfiguration,\n",
    "    SemanticPrioritizedFields,\n",
    "    SemanticField,\n",
    "    SearchField,\n",
    "    VectorSearch,\n",
    "    SemanticSearch,\n",
    "    HnswAlgorithmConfiguration,\n",
    "    HnswParameters,\n",
    "    VectorSearch,\n",
    "    VectorSearchAlgorithmKind,\n",
    "    VectorSearchProfile,\n",
    "    SearchIndex,\n",
    "    SearchField,\n",
    "    SearchFieldDataType,\n",
    "    SimpleField,\n",
    "    SearchableField,\n",
    "    VectorSearch,\n",
    "    ExhaustiveKnnParameters,\n",
    "    SearchIndex,\n",
    "    SearchField,\n",
    "    SearchFieldDataType,\n",
    "    SimpleField,\n",
    "    SearchableField,\n",
    "    SearchIndex,\n",
    "    SemanticConfiguration,\n",
    "    SemanticField,\n",
    "    SearchField,\n",
    "    VectorSearch,\n",
    "    HnswParameters,\n",
    "    VectorSearch,\n",
    "    VectorSearchAlgorithmKind,\n",
    "    VectorSearchAlgorithmMetric,\n",
    "    VectorSearchProfile,\n",
    ")\n",
    "\n",
    "# Load environment variables from .env file\n",
    "load_dotenv()\n",
    "\n",
    "# Define the target directory\n",
    "target_directory = os.getcwd()  # Get the current working directory\n",
    "\n",
    "# Move one directory back\n",
    "parent_directory = os.path.dirname(target_directory)\n",
    "\n",
    "# Check if the parent directory exists\n",
    "if os.path.exists(parent_directory):\n",
    "    # Change the current working directory to the parent directory\n",
    "    os.chdir(parent_directory)\n",
    "    print(f\"Directory changed to {os.getcwd()}\")\n",
    "else:\n",
    "    print(f\"Parent directory {parent_directory} does not exist.\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### **Indexing Policy Documents from Blob Storage Using the SDK (Push Model)**"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### **1. Use Document Intelligence to parse and read the PDF into text (Markdown)**"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2025-04-02 19:20:55,844 - micro - MainProcess - INFO     Container 'pre-auth-policies' already exists. (blob_helper.py:_create_container_if_not_exists:89)\n"
     ]
    }
   ],
   "source": [
    "from src.documentintelligence.document_intelligence_helper import AzureDocumentIntelligenceManager\n",
    "\n",
    "text_extractor = AzureDocumentIntelligenceManager()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2025-04-02 19:20:56,765 - micro - MainProcess - INFO     Blob URL detected. Extracting content. (document_intelligence_helper.py:analyze_document:78)\n",
      "2025-04-02 19:20:57,443 - micro - MainProcess - INFO     Downloaded blob 'policies_ocr/001.pdf' as bytes. (blob_helper.py:download_blob_to_bytes:311)\n"
     ]
    }
   ],
   "source": [
    "policy_raw_text_markdown = text_extractor.analyze_document(document_input=\"https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/001.pdf\", \n",
    "                                model_type=\"prebuilt-layout\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'<figure>\\n\\ncigna\\nhealthcare\\n\\n</figure>\\n\\n\\n# PRIOR AUTHORIZATION POLICY\\n\\nPOLICY:\\n\\nInflammatory Conditio'"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "policy_raw_text_markdown.content[:100]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### **2. Extract Metadata**\n",
    "\n",
    "- **Policy Name**: Extracted from document title or headers (e.g., \"Antiseizure Medications ‚Äì Epidiolex Prior Authorization Policy\").\n",
    "- **Payer Name**: Identifies which insurance company issued the policy (e.g., Cigna, UnitedHealthcare).\n",
    "- **Drug Name(s)**: The medications referenced in the policy (e.g., Epidiolex, Dupixent).\n",
    "- **Medical Specialties Involved**: Identifies if a policy is specific to Rheumatology, Neurology, Oncology, etc.\n",
    "- **Indications & Diseases Covered**: Disease categories linked to a policy (e.g., Crohn‚Äôs disease, epilepsy)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "from typing import List, Dict, Optional\n",
    "from pydantic import BaseModel\n",
    "import openai\n",
    "import os\n",
    "import time\n",
    "import requests\n",
    "from azure.core.credentials import AzureKeyCredential\n",
    "from utils.ml_logging import get_logger\n",
    "\n",
    "logger = get_logger()\n",
    "\n",
    "# --------------------------------------------------------------------------\n",
    "# Configure the Azure OpenAI client using key-based authentication.\n",
    "# --------------------------------------------------------------------------\n",
    "client = openai.AzureOpenAI(\n",
    "    api_version=\"2024-12-01-preview\",\n",
    "    azure_endpoint=\"https://pablo-m2areked-westeurope.cognitiveservices.azure.com\",\n",
    "    azure_deployment=\"gpt-4o-structured-outputs\",\n",
    "    api_key=os.getenv(\"AZURE_OPENAI_KEY_StructuredOutputs\")\n",
    "    )  # Ensure this env var is set.\n",
    "\n",
    "model_name = \"gpt-4o-structured-outputs\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "# ----------------- DEFINE POLICY METADATA MODEL -----------------\n",
    "class PolicyMetadata(BaseModel):\n",
    "    policy_name: str\n",
    "    payer_name: str\n",
    "    drug_names: List[str]\n",
    "    medical_specialties: List[str]\n",
    "    indications_diseases: List[str]\n",
    "    covered_diseases_icd_codes: Optional[List[str]]\n",
    "    covered_drug_codes: Optional[List[str]]\n",
    "\n",
    "    class Config:\n",
    "        extra = \"forbid\"\n",
    "\n",
    "# ----------------- ICD-10 LOOKUP FUNCTION -----------------\n",
    "def lookup_icd_codes_for_disease(disease: str, max_retries: int = 2) -> List[str]:\n",
    "    \"\"\"Fetches up to three ICD-10 codes for a given disease with retries on failure.\"\"\"\n",
    "\n",
    "    if not isinstance(disease, str) or not disease.strip():\n",
    "        logger.error(\"Invalid disease parameter provided.\")\n",
    "        return []\n",
    "\n",
    "    url = \"https://clinicaltables.nlm.nih.gov/api/icd10cm/v3/search\"\n",
    "    params = {\"sf\": \"code,name\", \"terms\": disease, \"maxList\": 3}\n",
    "\n",
    "    for attempt in range(max_retries + 1):\n",
    "        try:\n",
    "            logger.info(f\"[Attempt {attempt+1}] Fetching ICD-10 codes for disease: '{disease}' with params: {params}\")\n",
    "            resp = requests.get(url, params=params, timeout=10)\n",
    "            resp.raise_for_status()\n",
    "\n",
    "            if 'application/json' not in resp.headers.get('Content-Type', ''):\n",
    "                logger.error(f\"Unexpected content type: {resp.headers.get('Content-Type')}\")\n",
    "                return []\n",
    "\n",
    "            data = resp.json()\n",
    "            logger.debug(f\"Full ICD-10 API Response: {data}\")\n",
    "\n",
    "            # ‚úÖ Extract only the ICD-10 codes and ensure they are valid\n",
    "            icd_codes = [item for item in data[1] if isinstance(item, str) and len(item) > 3]\n",
    "\n",
    "            if icd_codes:\n",
    "                logger.info(f\"ICD-10 Codes Found for '{disease}': {icd_codes}\")\n",
    "                return icd_codes\n",
    "            else:\n",
    "                logger.warning(f\"No valid ICD-10 codes found for '{disease}'.\")\n",
    "                return []\n",
    "\n",
    "        except requests.RequestException as e:\n",
    "            logger.error(f\"ICD lookup failed for '{disease}' on attempt {attempt+1}: {e}\")\n",
    "            if attempt < max_retries:\n",
    "                logger.info(f\"Retrying ICD lookup for '{disease}'...\")\n",
    "                time.sleep(2)  # Wait before retrying\n",
    "\n",
    "    logger.error(f\"ICD lookup ultimately failed for '{disease}' after {max_retries+1} attempts.\")\n",
    "    return []\n",
    "\n",
    "\n",
    "# ----------------- RXNORM LOOKUP FUNCTION -----------------\n",
    "def lookup_drug_details(drug: str, max_retries: int = 2) -> List[str]:\n",
    "    \"\"\"Fetches RxNorm IDs for TAH-validated drugs with retries on failure.\"\"\"\n",
    "    \n",
    "    if not isinstance(drug, str) or not drug.strip():\n",
    "        logger.error(\"Invalid drug parameter provided.\")\n",
    "        return []\n",
    "\n",
    "    url = \"https://rxnav.nlm.nih.gov/REST/rxcui.json\"\n",
    "    params = {\"name\": drug}\n",
    "\n",
    "    for attempt in range(max_retries + 1):\n",
    "        try:\n",
    "            logger.info(f\"[Attempt {attempt+1}] Fetching RxNorm ID for drug: '{drug}' with params: {params}\")\n",
    "            resp = requests.get(url, params=params, timeout=10)\n",
    "            resp.raise_for_status()\n",
    "\n",
    "            if 'application/json' not in resp.headers.get('Content-Type', ''):\n",
    "                logger.error(f\"Unexpected content type: {resp.headers.get('Content-Type')}\")\n",
    "                return []\n",
    "\n",
    "            data = resp.json()\n",
    "            logger.debug(f\"Full RxNorm API Response: {data}\")\n",
    "\n",
    "            # Extract only the RxNorm IDs\n",
    "            rxnorm_ids = data.get(\"idGroup\", {}).get(\"rxnormId\", [])\n",
    "\n",
    "            if rxnorm_ids:\n",
    "                logger.info(f\"RxNorm IDs Found for '{drug}': {rxnorm_ids}\")\n",
    "                return rxnorm_ids\n",
    "            else:\n",
    "                logger.warning(f\"No RxNorm ID found for '{drug}'.\")\n",
    "                return []\n",
    "\n",
    "        except requests.RequestException as e:\n",
    "            logger.error(f\"Drug lookup failed for '{drug}' on attempt {attempt+1}: {e}\")\n",
    "            if attempt < max_retries:\n",
    "                logger.info(f\"Retrying RxNorm lookup for '{drug}'...\")\n",
    "                time.sleep(2)  # Wait before retrying\n",
    "\n",
    "    logger.error(f\"RxNorm lookup ultimately failed for '{drug}' after {max_retries+1} attempts.\")\n",
    "    return []\n",
    "\n",
    "\n",
    "# ----------------- FINAL ENRICHMENT FUNCTION -----------------\n",
    "def enrich_metadata(metadata: PolicyMetadata) -> PolicyMetadata:\n",
    "    \"\"\"Enrich extracted metadata with ICD-10 and RxNorm codes, only for TAH-validated terms.\"\"\"\n",
    "    enriched = metadata.model_copy()\n",
    "    enriched.covered_diseases_icd_codes = [\n",
    "        code for disease in metadata.indications_diseases\n",
    "        for code in lookup_icd_codes_for_disease(disease)\n",
    "    ]\n",
    "    enriched.covered_drug_codes = [\n",
    "        code for drug in metadata.drug_names\n",
    "        for code in lookup_drug_details(drug)\n",
    "    ]\n",
    "    return enriched\n",
    "# --------------------------------------------------------------------------\n",
    "# Extraction Phase: Use Azure OpenAI to parse policy text into the above schema.\n",
    "# --------------------------------------------------------------------------\n",
    "# Optimized function for metadata extraction\n",
    "def extract_policy_metadata(policy_text: str) -> PolicyMetadata:\n",
    "    messages = [\n",
    "        {\n",
    "            \"role\": \"system\",\n",
    "            \"content\": (\n",
    "                \"You are an advanced AI system specializing in extracting **structured metadata** from clinical policy documents. \"\n",
    "                \"Your goal is to achieve **100% accuracy** by leveraging **Tree of Thought reasoning, multi-step validation techniques, \"\n",
    "                \"and automated normalization of payer names, drug names, and medical conditions**.\\n\\n\"\n",
    "\n",
    "                \"### **1Ô∏è‚É£ Extract Policy Name (`policy_name`)** üìÑ\\n\"\n",
    "                \"- **Identify the official policy title** from document **headers, footers, or the first paragraph**.\\n\"\n",
    "                \"- **Ensure Standard Formatting:** Convert extracted titles into a **consistent naming format**.\\n\"\n",
    "                \"  - **Example Input (Raw OCR Extracted Text):**\\n\"\n",
    "                \"    - 'DUPIXENT (DUPILUMAB) - PRIOR AUTHORIZATION POLICY'\\n\"\n",
    "                \"    - 'Anthem BCBS Policy 2024: Prior Authorization - Dupixent'\\n\"\n",
    "                \"  - **Expected Standard Output:**\\n\"\n",
    "                \"    - 'Dupixent Prior Authorization Policy'\\n\\n\"\n",
    "\n",
    "                \"2Ô∏è‚É£ **Payer Name (payer_name) - AUTOMATIC NORMALIZATION ENABLED:**\\n\"\n",
    "                \"   - Locate in **headers, footers, disclaimers, or embedded watermarks**.\\n\"\n",
    "                \"   - Normalize using the following standardized mapping:\\n\"\n",
    "                \"     - 'Cigna', 'Cigna Healthcare', 'Cigna Corp' ‚Üí 'Cigna'\\n\"\n",
    "                \"     - 'Humana', 'Humana Inc', 'Humana Health Plan' ‚Üí 'Humana'\\n\"\n",
    "                \"     - 'United Healthcare', 'United Health Care', 'UHC' ‚Üí 'UnitedHealthcare'\\n\"\n",
    "                \"     - 'Anthem Blue Cross Blue Shield' ‚Üí 'Anthem BCBS'\\n\"\n",
    "                \"     - 'Blue Cross Blue Shield' ‚Üí 'BCBS'\\n\"\n",
    "                \"     - 'Kaiser Permanente' ‚Üí 'Kaiser Permanente'\\n\"\n",
    "                \"     - 'Aetna', 'Aetna Health Inc', 'Aetna Insurance' ‚Üí 'Aetna'\\n\"\n",
    "                \"     - 'WellCare Health Plans' ‚Üí 'WellCare'\\n\"\n",
    "                \"     - 'Medicare Advantage' ‚Üí 'Medicare'\\n\"\n",
    "                \"     - 'Medicaid' ‚Üí 'Medicaid'\\n\"\n",
    "                \"     - 'MVP Health Care' ‚Üí 'MVP HealthCare'\\n\"\n",
    "                \"     - 'HealthFirst' ‚Üí 'HealthFirst'\\n\"\n",
    "                \"     - 'Molina Healthcare' ‚Üí 'Molina Healthcare'\\n\"\n",
    "                \"     - 'Centene Corporation' ‚Üí 'Centene'\\n\"\n",
    "                \"     - 'Blue Shield of California' ‚Üí 'Blue Shield of California'\\n\"\n",
    "                \"     - 'Empire Blue Cross Blue Shield' ‚Üí 'Empire BCBS'\\n\"\n",
    "                \"     - 'Horizon Blue Cross Blue Shield' ‚Üí 'Horizon BCBS'\\n\"\n",
    "\n",
    "                \"3Ô∏è‚É£ **Drug Names (drug_names) - AUTOMATIC NORMALIZATION ENABLED:**\\n\"\n",
    "                \"   - Extract **all medications mentioned in the policy**.\\n\"\n",
    "                \"   - Include **both brand and generic names**.\\n\"\n",
    "                \"   - Normalize using **RxNorm drug database standards**.\\n\"\n",
    "\n",
    "                \"4Ô∏è‚É£ **Medical Specialties (medical_specialties):**\\n\"\n",
    "                \"   - Identify relevant **clinical specialties** (e.g., Neurology, Rheumatology, Oncology).\\n\"\n",
    "                \"   - Cross-check with **medical board designations** to avoid ambiguity.\\n\"\n",
    "\n",
    "                \"5Ô∏è‚É£ **Indications & Diseases (indications_diseases) - AUTOMATIC NORMALIZATION ENABLED:**\\n\"\n",
    "                \"   - Extract **every disease, condition, or indication mentioned**.\\n\"\n",
    "                \"   - Normalize to **ICD-10 classification**.\\n\"\n",
    "                \"   - Check **eligibility, exclusions, and coverage sections** for additional conditions.\\n\\n\"\n",
    "\n",
    "                \"### **General Guidelines:**\\n\"\n",
    "                \"- If a field is missing, return an **empty string (`\"\"`)** for text fields or an **empty list (`[]`)** for arrays.\\n\"\n",
    "                \"- Strictly **follow the JSON schema** without adding extra keys.\\n\"\n",
    "                \"- **Cross-validate extracted information** across multiple sections to prevent errors.\\n\"\n",
    "            )\n",
    "        },\n",
    "        {\n",
    "            \"role\": \"user\",\n",
    "            \"content\": (\n",
    "                \"Extract and normalize structured metadata from the following insurance policy document:\\n\\n\"\n",
    "                f\"{policy_text}\\n\\n\"\n",
    "                \"### **Output Schema (Strict JSON Format):**\\n\"\n",
    "                \"{\\n\"\n",
    "                '  \"policy_name\": \"The official title of the prior authorization policy.\",\\n'\n",
    "                '  \"payer_name\": \"The name of the insurance company, automatically normalized.\",\\n'\n",
    "                '  \"drug_names\": [\"List of all referenced drugs, including brand and generic, automatically normalized.\"],\\n'\n",
    "                '  \"medical_specialties\": [\"List of relevant clinical specialties (e.g., Neurology, Oncology).\"],\\n'\n",
    "                '  \"indications_diseases\": [\"List of all conditions covered under this policy, normalized to ICD-10 standards.\"]\\n'\n",
    "                \"}\"\n",
    "            )\n",
    "        }\n",
    "    ]\n",
    "\n",
    "    try:\n",
    "        response = client.beta.chat.completions.parse(\n",
    "            model=model_name,\n",
    "            messages=messages,\n",
    "            response_format=PolicyMetadata\n",
    "        )\n",
    "        metadata = response.choices[0].message.parsed\n",
    "\n",
    "        # Enrich metadata with ICD-10 and RxNorm codes\n",
    "        enriched_metadata = enrich_metadata(metadata)\n",
    "        enriched = enriched_metadata.model_dump()\n",
    "\n",
    "        return enriched\n",
    "    \n",
    "    except Exception as e:\n",
    "        logger.error(\"Error during extraction: %s\", e)\n",
    "        raise"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2025-04-02 19:21:30,192 - micro - MainProcess - INFO     [Attempt 1] Fetching ICD-10 codes for disease: 'Ankylosing spondylitis' with params: {'sf': 'code,name', 'terms': 'Ankylosing spondylitis', 'maxList': 3} (1126985018.py:lookup_icd_codes_for_disease:27)\n",
      "2025-04-02 19:21:30,356 - micro - MainProcess - INFO     ICD-10 Codes Found for 'Ankylosing spondylitis': ['M08.1', 'M45.6', 'M45.2'] (1126985018.py:lookup_icd_codes_for_disease:42)\n",
      "2025-04-02 19:21:30,358 - micro - MainProcess - INFO     [Attempt 1] Fetching ICD-10 codes for disease: 'Crohn's disease' with params: {'sf': 'code,name', 'terms': \"Crohn's disease\", 'maxList': 3} (1126985018.py:lookup_icd_codes_for_disease:27)\n",
      "2025-04-02 19:21:30,494 - micro - MainProcess - INFO     ICD-10 Codes Found for 'Crohn's disease': ['K50.90', 'K50.913', 'K50.914'] (1126985018.py:lookup_icd_codes_for_disease:42)\n",
      "2025-04-02 19:21:30,496 - micro - MainProcess - INFO     [Attempt 1] Fetching ICD-10 codes for disease: 'Hidradenitis suppurativa' with params: {'sf': 'code,name', 'terms': 'Hidradenitis suppurativa', 'maxList': 3} (1126985018.py:lookup_icd_codes_for_disease:27)\n",
      "2025-04-02 19:21:30,616 - micro - MainProcess - INFO     ICD-10 Codes Found for 'Hidradenitis suppurativa': ['L73.2'] (1126985018.py:lookup_icd_codes_for_disease:42)\n",
      "2025-04-02 19:21:30,617 - micro - MainProcess - INFO     [Attempt 1] Fetching ICD-10 codes for disease: 'Juvenile idiopathic arthritis' with params: {'sf': 'code,name', 'terms': 'Juvenile idiopathic arthritis', 'maxList': 3} (1126985018.py:lookup_icd_codes_for_disease:27)\n",
      "2025-04-02 19:21:30,729 - micro - MainProcess - WARNING  No valid ICD-10 codes found for 'Juvenile idiopathic arthritis'. (1126985018.py:lookup_icd_codes_for_disease:45)\n",
      "2025-04-02 19:21:30,731 - micro - MainProcess - INFO     [Attempt 1] Fetching ICD-10 codes for disease: 'Plaque psoriasis' with params: {'sf': 'code,name', 'terms': 'Plaque psoriasis', 'maxList': 3} (1126985018.py:lookup_icd_codes_for_disease:27)\n",
      "2025-04-02 19:21:30,846 - micro - MainProcess - WARNING  No valid ICD-10 codes found for 'Plaque psoriasis'. (1126985018.py:lookup_icd_codes_for_disease:45)\n",
      "2025-04-02 19:21:30,848 - micro - MainProcess - INFO     [Attempt 1] Fetching ICD-10 codes for disease: 'Psoriatic arthritis' with params: {'sf': 'code,name', 'terms': 'Psoriatic arthritis', 'maxList': 3} (1126985018.py:lookup_icd_codes_for_disease:27)\n",
      "2025-04-02 19:21:30,962 - micro - MainProcess - INFO     ICD-10 Codes Found for 'Psoriatic arthritis': ['L40.52'] (1126985018.py:lookup_icd_codes_for_disease:42)\n",
      "2025-04-02 19:21:30,964 - micro - MainProcess - INFO     [Attempt 1] Fetching ICD-10 codes for disease: 'Rheumatoid arthritis' with params: {'sf': 'code,name', 'terms': 'Rheumatoid arthritis', 'maxList': 3} (1126985018.py:lookup_icd_codes_for_disease:27)\n",
      "2025-04-02 19:21:31,073 - micro - MainProcess - INFO     ICD-10 Codes Found for 'Rheumatoid arthritis': ['M06.9', 'M05.9', 'M06.08'] (1126985018.py:lookup_icd_codes_for_disease:42)\n",
      "2025-04-02 19:21:31,075 - micro - MainProcess - INFO     [Attempt 1] Fetching ICD-10 codes for disease: 'Ulcerative colitis' with params: {'sf': 'code,name', 'terms': 'Ulcerative colitis', 'maxList': 3} (1126985018.py:lookup_icd_codes_for_disease:27)\n",
      "2025-04-02 19:21:31,196 - micro - MainProcess - INFO     ICD-10 Codes Found for 'Ulcerative colitis': ['K51.80', 'K51.813', 'K51.814'] (1126985018.py:lookup_icd_codes_for_disease:42)\n",
      "2025-04-02 19:21:31,198 - micro - MainProcess - INFO     [Attempt 1] Fetching ICD-10 codes for disease: 'Uveitis' with params: {'sf': 'code,name', 'terms': 'Uveitis', 'maxList': 3} (1126985018.py:lookup_icd_codes_for_disease:27)\n",
      "2025-04-02 19:21:31,306 - micro - MainProcess - INFO     ICD-10 Codes Found for 'Uveitis': ['H44.133', 'H44.131', 'H44.132'] (1126985018.py:lookup_icd_codes_for_disease:42)\n",
      "2025-04-02 19:21:31,310 - micro - MainProcess - INFO     [Attempt 1] Fetching ICD-10 codes for disease: 'Behcet's disease' with params: {'sf': 'code,name', 'terms': \"Behcet's disease\", 'maxList': 3} (1126985018.py:lookup_icd_codes_for_disease:27)\n",
      "2025-04-02 19:21:31,417 - micro - MainProcess - INFO     ICD-10 Codes Found for 'Behcet's disease': ['M35.2'] (1126985018.py:lookup_icd_codes_for_disease:42)\n",
      "2025-04-02 19:21:31,419 - micro - MainProcess - INFO     [Attempt 1] Fetching ICD-10 codes for disease: 'Pyoderma gangrenosum' with params: {'sf': 'code,name', 'terms': 'Pyoderma gangrenosum', 'maxList': 3} (1126985018.py:lookup_icd_codes_for_disease:27)\n",
      "2025-04-02 19:21:31,556 - micro - MainProcess - WARNING  No valid ICD-10 codes found for 'Pyoderma gangrenosum'. (1126985018.py:lookup_icd_codes_for_disease:45)\n",
      "2025-04-02 19:21:31,559 - micro - MainProcess - INFO     [Attempt 1] Fetching ICD-10 codes for disease: 'Sarcoidosis' with params: {'sf': 'code,name', 'terms': 'Sarcoidosis', 'maxList': 3} (1126985018.py:lookup_icd_codes_for_disease:27)\n",
      "2025-04-02 19:21:31,692 - micro - MainProcess - INFO     ICD-10 Codes Found for 'Sarcoidosis': ['D86.9', 'D86.2', 'D86.0'] (1126985018.py:lookup_icd_codes_for_disease:42)\n",
      "2025-04-02 19:21:31,693 - micro - MainProcess - INFO     [Attempt 1] Fetching ICD-10 codes for disease: 'Scleritis' with params: {'sf': 'code,name', 'terms': 'Scleritis', 'maxList': 3} (1126985018.py:lookup_icd_codes_for_disease:27)\n",
      "2025-04-02 19:21:31,820 - micro - MainProcess - INFO     ICD-10 Codes Found for 'Scleritis': ['B02.34', 'H15.003', 'H15.013'] (1126985018.py:lookup_icd_codes_for_disease:42)\n",
      "2025-04-02 19:21:31,821 - micro - MainProcess - INFO     [Attempt 1] Fetching ICD-10 codes for disease: 'Axial spondyloarthritis' with params: {'sf': 'code,name', 'terms': 'Axial spondyloarthritis', 'maxList': 3} (1126985018.py:lookup_icd_codes_for_disease:27)\n",
      "2025-04-02 19:21:31,945 - micro - MainProcess - INFO     ICD-10 Codes Found for 'Axial spondyloarthritis': ['M45.A1', 'M45.A2', 'M45.A3'] (1126985018.py:lookup_icd_codes_for_disease:42)\n",
      "2025-04-02 19:21:31,947 - micro - MainProcess - INFO     [Attempt 1] Fetching RxNorm ID for drug: 'Abrilada (adalimumab-afzb)' with params: {'name': 'Abrilada (adalimumab-afzb)'} (1126985018.py:lookup_drug_details:71)\n",
      "2025-04-02 19:21:32,168 - micro - MainProcess - WARNING  No RxNorm ID found for 'Abrilada (adalimumab-afzb)'. (1126985018.py:lookup_drug_details:89)\n",
      "2025-04-02 19:21:32,172 - micro - MainProcess - INFO     [Attempt 1] Fetching RxNorm ID for drug: 'adalimumab-aacf' with params: {'name': 'adalimumab-aacf'} (1126985018.py:lookup_drug_details:71)\n",
      "2025-04-02 19:21:32,322 - micro - MainProcess - INFO     RxNorm IDs Found for 'adalimumab-aacf': ['2640849'] (1126985018.py:lookup_drug_details:86)\n",
      "2025-04-02 19:21:32,328 - micro - MainProcess - INFO     [Attempt 1] Fetching RxNorm ID for drug: 'adalimumab-adaz' with params: {'name': 'adalimumab-adaz'} (1126985018.py:lookup_drug_details:71)\n",
      "2025-04-02 19:21:32,487 - micro - MainProcess - INFO     RxNorm IDs Found for 'adalimumab-adaz': ['2641642'] (1126985018.py:lookup_drug_details:86)\n",
      "2025-04-02 19:21:32,488 - micro - MainProcess - INFO     [Attempt 1] Fetching RxNorm ID for drug: 'adalimumab-adbm' with params: {'name': 'adalimumab-adbm'} (1126985018.py:lookup_drug_details:71)\n",
      "2025-04-02 19:21:32,636 - micro - MainProcess - INFO     RxNorm IDs Found for 'adalimumab-adbm': ['2103477'] (1126985018.py:lookup_drug_details:86)\n",
      "2025-04-02 19:21:32,638 - micro - MainProcess - INFO     [Attempt 1] Fetching RxNorm ID for drug: 'adalimumab-fkjp' with params: {'name': 'adalimumab-fkjp'} (1126985018.py:lookup_drug_details:71)\n",
      "2025-04-02 19:21:32,783 - micro - MainProcess - INFO     RxNorm IDs Found for 'adalimumab-fkjp': ['2640402'] (1126985018.py:lookup_drug_details:86)\n",
      "2025-04-02 19:21:32,785 - micro - MainProcess - INFO     [Attempt 1] Fetching RxNorm ID for drug: 'adalimumab-ryvk' with params: {'name': 'adalimumab-ryvk'} (1126985018.py:lookup_drug_details:71)\n",
      "2025-04-02 19:21:32,939 - micro - MainProcess - INFO     RxNorm IDs Found for 'adalimumab-ryvk': ['2677776'] (1126985018.py:lookup_drug_details:86)\n",
      "2025-04-02 19:21:32,945 - micro - MainProcess - INFO     [Attempt 1] Fetching RxNorm ID for drug: 'Humira (adalimumab)' with params: {'name': 'Humira (adalimumab)'} (1126985018.py:lookup_drug_details:71)\n",
      "2025-04-02 19:21:33,099 - micro - MainProcess - WARNING  No RxNorm ID found for 'Humira (adalimumab)'. (1126985018.py:lookup_drug_details:89)\n",
      "2025-04-02 19:21:33,101 - micro - MainProcess - INFO     [Attempt 1] Fetching RxNorm ID for drug: 'Amjevita (adalimumab-atto)' with params: {'name': 'Amjevita (adalimumab-atto)'} (1126985018.py:lookup_drug_details:71)\n",
      "2025-04-02 19:21:33,258 - micro - MainProcess - WARNING  No RxNorm ID found for 'Amjevita (adalimumab-atto)'. (1126985018.py:lookup_drug_details:89)\n",
      "2025-04-02 19:21:33,260 - micro - MainProcess - INFO     [Attempt 1] Fetching RxNorm ID for drug: 'Cyltezo (adalimumab-adbm)' with params: {'name': 'Cyltezo (adalimumab-adbm)'} (1126985018.py:lookup_drug_details:71)\n",
      "2025-04-02 19:21:33,402 - micro - MainProcess - WARNING  No RxNorm ID found for 'Cyltezo (adalimumab-adbm)'. (1126985018.py:lookup_drug_details:89)\n",
      "2025-04-02 19:21:33,404 - micro - MainProcess - INFO     [Attempt 1] Fetching RxNorm ID for drug: 'Hadlima (adalimumab-bwwd)' with params: {'name': 'Hadlima (adalimumab-bwwd)'} (1126985018.py:lookup_drug_details:71)\n",
      "2025-04-02 19:21:33,543 - micro - MainProcess - WARNING  No RxNorm ID found for 'Hadlima (adalimumab-bwwd)'. (1126985018.py:lookup_drug_details:89)\n",
      "2025-04-02 19:21:33,549 - micro - MainProcess - INFO     [Attempt 1] Fetching RxNorm ID for drug: 'Hulio (adalimumab-fkjp)' with params: {'name': 'Hulio (adalimumab-fkjp)'} (1126985018.py:lookup_drug_details:71)\n",
      "2025-04-02 19:21:33,734 - micro - MainProcess - WARNING  No RxNorm ID found for 'Hulio (adalimumab-fkjp)'. (1126985018.py:lookup_drug_details:89)\n",
      "2025-04-02 19:21:33,736 - micro - MainProcess - INFO     [Attempt 1] Fetching RxNorm ID for drug: 'Hyrimoz (adalimumab-adaz)' with params: {'name': 'Hyrimoz (adalimumab-adaz)'} (1126985018.py:lookup_drug_details:71)\n",
      "2025-04-02 19:21:33,903 - micro - MainProcess - WARNING  No RxNorm ID found for 'Hyrimoz (adalimumab-adaz)'. (1126985018.py:lookup_drug_details:89)\n",
      "2025-04-02 19:21:33,906 - micro - MainProcess - INFO     [Attempt 1] Fetching RxNorm ID for drug: 'Idacio (adalimumab-aacf)' with params: {'name': 'Idacio (adalimumab-aacf)'} (1126985018.py:lookup_drug_details:71)\n",
      "2025-04-02 19:21:34,064 - micro - MainProcess - WARNING  No RxNorm ID found for 'Idacio (adalimumab-aacf)'. (1126985018.py:lookup_drug_details:89)\n",
      "2025-04-02 19:21:34,066 - micro - MainProcess - INFO     [Attempt 1] Fetching RxNorm ID for drug: 'Simlandi (adalimumab-ryvk)' with params: {'name': 'Simlandi (adalimumab-ryvk)'} (1126985018.py:lookup_drug_details:71)\n",
      "2025-04-02 19:21:34,227 - micro - MainProcess - WARNING  No RxNorm ID found for 'Simlandi (adalimumab-ryvk)'. (1126985018.py:lookup_drug_details:89)\n",
      "2025-04-02 19:21:34,228 - micro - MainProcess - INFO     [Attempt 1] Fetching RxNorm ID for drug: 'Yuflyma (adalimumab-aaty)' with params: {'name': 'Yuflyma (adalimumab-aaty)'} (1126985018.py:lookup_drug_details:71)\n",
      "2025-04-02 19:21:34,381 - micro - MainProcess - WARNING  No RxNorm ID found for 'Yuflyma (adalimumab-aaty)'. (1126985018.py:lookup_drug_details:89)\n",
      "2025-04-02 19:21:34,382 - micro - MainProcess - INFO     [Attempt 1] Fetching RxNorm ID for drug: 'Yusimry (adalimumab-aqvh)' with params: {'name': 'Yusimry (adalimumab-aqvh)'} (1126985018.py:lookup_drug_details:71)\n",
      "2025-04-02 19:21:34,562 - micro - MainProcess - WARNING  No RxNorm ID found for 'Yusimry (adalimumab-aqvh)'. (1126985018.py:lookup_drug_details:89)\n"
     ]
    }
   ],
   "source": [
    "extract_policy_metadata = extract_policy_metadata(policy_raw_text_markdown.content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'policy_name': 'Inflammatory Conditions - Adalimumab Products Prior Authorization Policy',\n",
       " 'payer_name': 'Cigna',\n",
       " 'drug_names': ['Abrilada (adalimumab-afzb)',\n",
       "  'adalimumab-aacf',\n",
       "  'adalimumab-adaz',\n",
       "  'adalimumab-adbm',\n",
       "  'adalimumab-fkjp',\n",
       "  'adalimumab-ryvk',\n",
       "  'Humira (adalimumab)',\n",
       "  'Amjevita (adalimumab-atto)',\n",
       "  'Cyltezo (adalimumab-adbm)',\n",
       "  'Hadlima (adalimumab-bwwd)',\n",
       "  'Hulio (adalimumab-fkjp)',\n",
       "  'Hyrimoz (adalimumab-adaz)',\n",
       "  'Idacio (adalimumab-aacf)',\n",
       "  'Simlandi (adalimumab-ryvk)',\n",
       "  'Yuflyma (adalimumab-aaty)',\n",
       "  'Yusimry (adalimumab-aqvh)'],\n",
       " 'medical_specialties': ['Rheumatology',\n",
       "  'Gastroenterology',\n",
       "  'Dermatology',\n",
       "  'Ophthalmology'],\n",
       " 'indications_diseases': ['Ankylosing spondylitis',\n",
       "  \"Crohn's disease\",\n",
       "  'Hidradenitis suppurativa',\n",
       "  'Juvenile idiopathic arthritis',\n",
       "  'Plaque psoriasis',\n",
       "  'Psoriatic arthritis',\n",
       "  'Rheumatoid arthritis',\n",
       "  'Ulcerative colitis',\n",
       "  'Uveitis',\n",
       "  \"Behcet's disease\",\n",
       "  'Pyoderma gangrenosum',\n",
       "  'Sarcoidosis',\n",
       "  'Scleritis',\n",
       "  'Axial spondyloarthritis'],\n",
       " 'covered_diseases_icd_codes': ['M08.1',\n",
       "  'M45.6',\n",
       "  'M45.2',\n",
       "  'K50.90',\n",
       "  'K50.913',\n",
       "  'K50.914',\n",
       "  'L73.2',\n",
       "  'L40.52',\n",
       "  'M06.9',\n",
       "  'M05.9',\n",
       "  'M06.08',\n",
       "  'K51.80',\n",
       "  'K51.813',\n",
       "  'K51.814',\n",
       "  'H44.133',\n",
       "  'H44.131',\n",
       "  'H44.132',\n",
       "  'M35.2',\n",
       "  'D86.9',\n",
       "  'D86.2',\n",
       "  'D86.0',\n",
       "  'B02.34',\n",
       "  'H15.003',\n",
       "  'H15.013',\n",
       "  'M45.A1',\n",
       "  'M45.A2',\n",
       "  'M45.A3'],\n",
       " 'covered_drug_codes': ['2640849', '2641642', '2103477', '2640402', '2677776']}"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "extract_policy_metadata"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 3. **Chunk Documents**"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_text_splitters import MarkdownHeaderTextSplitter\n",
    "\n",
    "headers_to_split_on = [\n",
    "    (\"#\", \"Header 1\"),\n",
    "    (\"##\", \"Header 2\"),\n",
    "    (\"###\", \"Header 3\"),\n",
    "    (\"####\", \"Header 4\")\n",
    "]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "splitter = MarkdownHeaderTextSplitter(headers_to_split_on=headers_to_split_on)\n",
    "chunks = splitter.split_text(policy_raw_text_markdown.content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={}, page_content='<figure>  \\ncigna\\nhealthcare  \\n</figure>'),\n",
       " Document(metadata={'Header 1': 'PRIOR AUTHORIZATION POLICY'}, page_content='POLICY:  \\nInflammatory Conditions - Adalimumab Products Prior Authorization  \\nPolicy  \\n¬∑ Abrilada‚Ñ¢ (adalimumab-afzb subcutaneous injection - Pfizer)  \\n¬∑ adalimumab-aacf subcutaneous injection (Fresenius Kabi)  \\n¬∑ adalimumab-adaz subcutaneous injection (Sandoz/Novartis)  \\n¬∑ adalimumab-adbm subcutaneous injection (Boehringer Ingelheim)  \\n¬∑ adalimumab-fkjp subcutaneous injection (Mylan)  \\n¬∑ adalimumab-ryvk subcutaneous injection (Teva/Alvotech)  \\n¬∑ Amjevita¬Æ (adalimumab-atto subcutaneous injection - Amgen)  \\n¬∑ Cyltezo¬Æ (adalimumab-adbm subcutaneous injection - Boehringer\\nIngelheim)  \\n¬∑ Hadlima‚Ñ¢ (adalimumab-bwwd\\nsubcutaneous\\ninjection\\n‚Äì  \\nOrganon/Samsung Bioepis)  \\n¬∑ Hulio¬Æ (adalimumab-fkjp subcutaneous injection - Mylan)  \\n¬∑ Humira¬Æ (adalimumab subcutaneous injection - AbbVie, Cordavis)  \\n. Hyrimoz¬Æ (adalimumab-adaz\\nsubcutaneous\\nSandoz/Novartis, Cordavis)\\ninjection\\n‚Äì  \\n¬∑ Idacio¬Æ (adalimumab-aacf subcutaneous injection - Fresenius Kabi)  \\n¬∑ Simlandi¬Æ (adalimumab-ryvk subcutaneous injection -\\nTeva/Alvotech)  \\n¬∑ Yuflyma¬Æ (adalimumab-aaty subcutaneous injection - Celltrion)  \\n¬∑ Yusimry‚Ñ¢ (adalimuamb-aqvh subcutaneous injection - Coherus)  \\nREVIEW DATE: 03/27/2024; selected revision 04/03/2024, 09/11/2024'),\n",
       " Document(metadata={'Header 1': 'PRIOR AUTHORIZATION POLICY', 'Header 2': 'INSTRUCTIONS FOR USE'}, page_content=\"THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA\\nCOMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE\\nDETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE\\nCLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS\\nADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP\\nSERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN\\nDOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR\\nEXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE\\nPOLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE\\nCOVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY\\nDETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE\\nREQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY\\nAPPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE\\nSPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL\\nDIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE\\nDETERMINATIONS. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES\\nARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS,\\nDELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.\"),\n",
       " Document(metadata={'Header 1': 'CIGNA NATIONAL FORMULARY COVERAGE:'}, page_content='Page 1 of 21 - Cigna National Formulary Coverage - Policy:Inflammatory Conditions - Adalimumab Products Prior\\nAuthorization Policy  \\n<!-- PageBreak -->'),\n",
       " Document(metadata={'Header 1': 'CIGNA NATIONAL FORMULARY COVERAGE:', 'Header 2': 'OVERVIEW'}, page_content=\"Adalimumab products are tumor necrosis factor inhibitors (TNFis) approved for the following\\nuses: 1  \\n¬∑ Ankylosing spondylitis, for reducing signs and symptoms in patients with active\\ndisease.  \\n¬∑ Crohn's disease, for treatment of moderately to severely active disease in patients\\n‚â• 6 years of age.  \\n¬∑ Hidradenitis suppurativa, for the treatment of moderate to severe disease in\\npatients ‚â• 12 years of age.  \\n¬∑ Juvenile idiopathic arthritis (JIA), ¬± methotrexate for reducing signs and\\nsymptoms of moderately to severely active polyarticular disease in patients ‚â• 2\\nyears of age.  \\n¬∑ Plaque psoriasis, for the treatment of adults with moderate to severe chronic\\ndisease who are candidates for systemic therapy or phototherapy and when other\\nsystemic therapies are medically less appropriate.  \\n¬∑ Psoriatic arthritis (PsA), ¬± conventional synthetic disease-modifying\\nantirheumatic drugs (DMARDs), for reducing the signs and symptoms of active\\narthritis, inhibiting the progression of structural damage, and improving physical\\nfunction.  \\n. Rheumatoid arthritis, + methotrexate or other conventional synthetic DMARDS to\\nreduce the signs and symptoms, induce major clinical response, inhibit the\\nprogression of structural damage, and improve physical function in adults with\\nmoderately to severely active disease.  \\n¬∑ Ulcerative colitis, for treatment of moderately to severely active disease in patients\\n‚â• 5 years of age. However, efficacy has not been established in patients with\\nulcerative colitis who have lost response or were intolerant to another TNFi.  \\n¬∑ Uveitis, in patients ‚â• 2 years of age with noninfectious intermediate, posterior, and\\npanuveitis.\"),\n",
       " Document(metadata={'Header 1': 'CIGNA NATIONAL FORMULARY COVERAGE:', 'Header 2': 'OVERVIEW', 'Header 3': 'Guidelines'}, page_content='TNFis are featured prominently in guidelines for treatment of inflammatory conditions.  \\n¬∑ Ankylosing Spondylitis and Spondyloarthritis: Guidelines for ankylosing\\nspondylitis and non-radiographic axial spondylitis are published by the American\\nCollege of Rheumatology (ACR)/Spondylitis Association of America/Spondyloarthritis\\nResearch and Treatment Network (2019).3 TNFis are recommended as the initial\\nbiologic. In those who are secondary non-responders to a TNFi, a second TNFi is\\nrecommended over switching out of the class.  \\n¬∑ Crohn\\'s Disease: The American College of Gastroenterology (ACG) has guidelines\\nfor Crohn\\'s disease (2018).4 TNFis are listed as an option for disease that is resistant\\nto corticosteroids, severely active disease, perianal fistulizing disease, and\\nmaintenance of remission. In post-operative Crohn\\'s disease, a TNFi should be\\nstarted within 4 weeks of surgery to prevent recurrence. Guidelines from the\\nAmerican Gastroenterological Association (AGA) [2021] include TNFis among the\\ntherapies for moderate to severe Crohn\\'s disease, for induction and maintenance of\\nremission. 17  \\n¬∑ Hidradenitis Suppurativa: British guidelines (2018) recommend consideration of\\nadalimumab for those with moderate to severe disease who do not respond to\\nconventional therapy.19  \\n¬∑ JIA: There are guidelines from ACR and the Arthritis Foundation for the treatment\\nof JIA (2021) which address oligoarthritis and temporomandibular joint (TMJ)\\narthritis. For oligoarthritis, a biologic is recommended following a trial of a  \\n3 Pages - Cigna National Formulary Coverage - Policy:Inflammatory Conditions - Adalimumab Products Prior\\nAuthorization Policy  \\n<!-- PageBreak -->  \\nconventional synthetic DMARD.6 In patients with TMJ arthritis, scheduled\\nnonsteroidal anti-inflammatory drugs (NSAIDs) and/or intra-articular glucocorticoids\\nare recommended first-line. A biologic is a therapeutic option if there is an\\ninadequate response or intolerance. Additionally, rapid escalation to a biologic ¬±\\nconventional synthetic DMARD (methotrexate preferred) is often appropriate given\\nthe impact and destructive nature of TMJ arthritis. In these guidelines, there is not a\\npreferred biologic that should be initiated for JIA. ACR guidelines (2019) are also\\navailable specifically for juvenile non-systemic polyarthritis, sacroiliitis, and\\nenthesitis.5 TNFis are the biologics recommended for polyarthritis, sacroiliitis, and\\nenthesitis. Biologics are recommended following other therapies (e.g., following\\nDMARDs for active polyarthritis or following an NSAID for active JIA with sacroiliitis\\nor enthesitis). However, there are situations where initial therapy with a biologic may\\nbe preferred over other conventional therapies (e.g., if there is involvement of high-\\nrisk joints such as the cervical spine, wrist, or hip; high disease activity; and/or\\nthose judged to be at high risk of disabling joint damage).  \\n¬∑ Plaque Psoriasis: Guidelines from the American Academy of Dermatologists and\\nNational Psoriasis Foundation (2019) recommend adalimumab as a monotherapy\\ntreatment option for adults with moderate to severe disease.7  \\n¬∑ PsA: Guidelines from ACR (2019) recommend TNFis over other biologics for use in\\ntreatment-na√Øve patients with PsA and in those who were previously treated with an\\noral therapy.8  \\n¬∑ Rheumatoid Arthritis: Guidelines from ACR (2021) recommend addition of a\\nbiologic or a targeted synthetic DMARD for a patient taking the maximum tolerated\\ndose of methotrexate who is not at target.2  \\n. Ulcerative Colitis: Guidelines from the ACG for ulcerative colitis (2019) note that\\nthe following agents can be used for induction of remission in moderately to severely\\nactive disease: budesonide extended-release tablets, oral or intravenous systemic\\ncorticosteroids, Entyvio¬Æ (vedolizumab intravenous infusion), Xeljanz¬Æ/XR (tofacitinib\\ntablets/extended-release tablets), or TNFis.9 Guidelines from the AGA (2020)\\nrecommend Xeljanz only after failure of or intolerance to a TNFi.10 In addition to the\\napproved indication, clinical guidelines for the management of pouchitis (2009)\\nindicate that first-line therapy for pouchitis is antibiotic therapy (e.g. metronidazole,\\nciprofloxacin).11 Other treatment options include maintenance probiotics, oral or\\ntopical budesonide, anti-inflammatory drugs (e.g., mesalamine), or\\nimmunosuppressive agents (e.g., infliximab).  \\n. Uveitis and Ocular Inflammatory Disorders: American Academy of\\nOphthalmology (AAO) guidelines (2014) note that adalimumab may be used in\\npatients with uveitis due to various causes (e.g., spondyloarthropathy-associated or\\nhuman leukocyte antigen [HLA]-B27-associated uveitis, JIA-associated uveitis, and\\nother posterior uveitides and panuveitis syndromes).12 Adalimumab should be\\nconsidered second-line in vision-threatening JIA-associated uveitis when\\nmethotrexate has failed or is not tolerated (strong recommendation) and may be\\nused as corticosteroid-sparing treatment for vision-threatening chronic uveitis from\\nseronegative spondyloarthropathy (strong recommendation). Adalimumab may also\\nbe considered in other patients who have vision-threatening or corticosteroid-\\ndependent disease who have failed first-line therapies. Adalimumab should be\\nconsidered as a second-line immunomodulatory agent for severe ocular inflammatory\\nconditions including chronic and severe scleritis. ACR/Arthritis Federation guidelines\\n(2019) for uveitis associated with JIA make recommendations for use of conventional\\nsystemic DMARDs and biologics. In patients with severe active chronic anterior\\nuveitis associated with sight-threatening complications, a TNFi (monoclonal antibody)\\n\\\\+ methotrexate is recommended.19  \\n<!-- PageFooter=\"3 Pages - Cigna National Formulary Coverage - Policy:Inflammatory Conditions - Adalimumab Products Prior Authorization Policy\" -->\\n<!-- PageBreak -->'),\n",
       " Document(metadata={'Header 1': 'CIGNA NATIONAL FORMULARY COVERAGE:', 'Header 2': 'Other Uses with Supportive Evidence'}, page_content=\"There are guidelines and/or published data supporting the use of adalimumab products in\\nthe following conditions:  \\n. Behcet's Disease: The European Union Against Rheumatism (EULAR)\\nrecommendations (2018) include TNFis for initial or recurrent sight-threatening\\nuveitis.13 For patients refractory to first-line treatments (e.g., corticosteroids), TNFis\\nare among the treatment options for mucocutaneous manifestations, venous\\nthrombosis, severe or refractory gastrointestinal disease, and recurrent/chronic joint\\ninvolvement. Recommendations for the use of TNFis in ocular inflammatory\\ndisorders from the AAO (2014) note that TNFis may be used first-line in patients with\\nophthalmic manifestations of Behcet's disease and for acute exacerbations of\\npreexisting Behcet's disease. 12  \\n¬∑ Pyoderma Gangrenosum: Although guidelines are not current, multiple topical\\nand systemic therapies have been used for pyoderma gangrenosum. Oral prednisone\\nis the most common initial immunosuppressant medication. 14 Other systemic\\ntherapies include cyclosporine, methotrexate, azathioprine, cyclophosphamide,\\nmycophenolate mofetil, and TNFis (i.e., infliximab, etanercept, and adalimumab\\nproducts). In case reports, TNFis have been effective.  \\n¬∑ Sarcoidosis: According to European Respiratory Society guidelines for sarcoidosis\\n(2021), a TNFi is recommended after a trial of glucocorticoids and\\nimmunosuppressants for pulmonary and neurosarcoidosis.15\"),\n",
       " Document(metadata={'Header 1': 'CIGNA NATIONAL FORMULARY COVERAGE:', 'Header 2': 'POLICY STATEMENT'}, page_content='Prior Authorization is recommended for prescription benefit coverage of adalimumab\\nproducts. All approvals are provided for the duration noted below. In cases where the\\napproval is authorized in months, 1 month is equal to 30 days. Because of the specialized\\nskills required for evaluation and diagnosis of patients treated with adalimumab products as\\nwell as the monitoring required for adverse events and long-term efficacy, initial approval\\nrequires the agent to be prescribed by or in consultation with a physician who specializes in\\nthe condition being treated.  \\n¬∑ Abrilada‚Ñ¢ (adalimumab-afzb subcutaneous injection - Pfizer)  \\n¬∑ adalimumab-aacf subcutaneous injection (Fresenius Kabi)  \\n¬∑ adalimumab-adaz subcutaneous injection (Sandoz/Novartis)  \\n¬∑ adalimumab-adbm subcutaneous injection (Boehringer Ingelheim)  \\n¬∑ adalimumab-fkjp subcutaneous injection (Mylan)  \\n¬∑ adalimumab-ryvk subcutaneous injection (Teva/Alvotech)  \\n¬∑ Amjevita (adalimumab-atto subcutaneous injection - Amgen)  \\n¬∑ Cyltezo¬Æ (adalimumab-adbm subcutaneous injection - Boehringer\\nIngelheim)  \\n¬∑ Hadlima‚Ñ¢ (adalimumab-bwwd subcutaneous injection - Organon/Samsung\\nBioepis)  \\n. Hulio¬Æ (adalimumab-fkjp subcutaneous injection - Mylan)  \\n¬∑ Humira¬Æ (adalimumab subcutaneous injection - AbbVie, Cordavis)  \\n¬∑ Hyrimoz¬Æ (adalimumab-adaz subcutaneous injection - Sandoz/Novartis,\\nCordavis)  \\n¬∑ Idacio¬Æ (adalimumab-aacf subcutaneous injection - Fresenius Kabi)  \\n¬∑ Simlandi¬Æ (adalimumab-ryvk subcutaneous injection - Teva/Alvotech)  \\n¬∑ Yuflyma¬Æ (adalimumab-aaty subcutaneous injection - Celltrion)  \\n¬∑ Yusimry‚Ñ¢ (adalimuamb-aqvh subcutaneous injection - Coherus)  \\nis(are) covered as medically necessary when the following criteria is(are) met for\\nFDA-approved indication(s) or other uses with supportive evidence (if applicable):  \\n3 Pages - Cigna National Formulary Coverage - Policy:Inflammatory Conditions - Adalimumab Products Prior\\nAuthorization Policy  \\n<!-- PageBreak -->'),\n",
       " Document(metadata={'Header 1': 'FDA-Approved Indications'}, page_content='1\\\\. Ankylosing Spondylitis. Approve for the duration noted if the patient meets ONE of\\nthe following (A or B):  \\nA) Initial Therapy. Approve for 6 months if the patient meets BOTH of the following (i\\nand ii):  \\ni. Patient is ‚â• 18 years of age; AND  \\nii. The medication is prescribed by or in consultation with a rheumatologist.  \\nB) Patient is Currently Receiving an Adalimumab Product. Approve for 1 year if the\\npatient meets BOTH of the following (i and ii):  \\ni. Patient has been established on therapy for at least 6 months; AND\\nNote: A patient who has received < 6 months of therapy or who is restarting\\ntherapy with an adalimumab product is reviewed under criterion A (Initial\\nTherapy).  \\nii. Patient meets at least ONE of the following (a or b):  \\na) When assessed by at least one objective measure, patient experienced a\\nbeneficial clinical response from baseline (prior to initiating an adalimumab\\nproduct); OR\\nNote: Examples of objective measures include Ankylosing Spondylitis Disease\\nActivity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL),\\nBath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing\\nSpondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global\\nScore (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI),\\nDougados Functional Index (DFI), Health Assessment Questionnaire for the\\nSpondyloarthropathies (HAQ-S), and/or serum markers (e.g., C-reactive\\nprotein, erythrocyte sedimentation rate).  \\nb) Compared with baseline (prior to initiating an adalimumab product), patient\\nexperienced an improvement in at least one symptom, such as decreased\\npain or stiffness, or improvement in function or activities of daily living.  \\n2\\\\. Crohn\\'s Disease. Approve for the duration noted if the patient meets ONE of the\\nfollowing (A or B):  \\nA) Initial Therapy. Approve for 6 months if the patient meets ALL of the following (i, ii,\\nand iii):  \\ni. Patient is ‚â• 6 years of age; AND  \\nii. Patient meets ONE of the following (a, b, c, or d):  \\na) Patient has tried or is currently taking corticosteroids, or corticosteroids are\\ncontraindicated in this patient; OR\\nNote: Examples of corticosteroids are prednisone or methylprednisolone.  \\nb) Patient has tried one other conventional systemic therapy for Crohn\\'s disease;\\nOR\\nNote: Examples of conventional systemic therapy for Crohn\\'s disease include\\nazathioprine, 6-mercaptopurine, or methotrexate. An exception to the\\nrequirement for a trial of or contraindication to steroids or a trial of one other\\nconventional systemic agent can be made if the patient has already tried at\\nleast one biologic other than the requested medication. A biosimilar of the\\nrequested biologic does not count. Refer to Appendix for examples of biologics\\nused for Crohn\\'s disease. A trial of mesalamine does not count as a systemic\\nagent for Crohn\\'s disease.  \\nc) Patient has enterocutaneous (perianal or abdominal) or rectovaginal fistulas;\\nOR  \\n3 Pages - Cigna National Formulary Coverage - Policy:Inflammatory Conditions - Adalimumab Products Prior\\nAuthorization Policy  \\n<!-- PageBreak -->  \\nd) Patient had ileocolonic resection (to reduce the chance of Crohn\\'s disease\\nrecurrence); AND  \\niii. The medication is prescribed by or in consultation with a gastroenterologist.  \\nB) Patient is Currently Receiving an Adalimumab Product. Approve for 1 year if the\\npatient meets BOTH of the following (i and ii):  \\ni. Patient has been established on therapy for at least 6 months; AND\\nNote: A patient who has received < 6 months of therapy or who is restarting\\ntherapy with an adalimumab product is reviewed under criterion A (Initial\\nTherapy).  \\nii. Patient meets at least ONE of the following (a or b):  \\na) When assessed by at least one objective measure, patient experienced a\\nbeneficial clinical response from baseline (prior to initiating an adalimumab\\nproduct); OR  \\nNote: Examples of objective measures include fecal markers (e.g., fecal\\nlactoferrin, fecal calprotectin), serum markers (e.g., C-reactive protein),\\nimaging studies (magnetic resonance enterography [MRE], computed\\ntomography enterography [CTE]), endoscopic assessment, and/or reduced\\ndose of corticosteroids.  \\nb) Compared with baseline (prior to initiating an adalimumab product), patient\\nexperienced an improvement in at least one symptom, such as decreased\\npain, fatigue, stool frequency, and/or blood in stool.  \\n3\\\\. Juvenile Idiopathic Arthritis (JIA) [or juvenile rheumatoid arthritis]\\n{regardless of type of onset}. Approve for the duration noted if the patient meets\\nONE of the following (A or B):  \\nNote: This includes a patient with juvenile spondyloarthropathy/active sacroiliac\\narthritis.  \\nA) Initial Therapy. Approve for 6 months if the patient meets ALL of the following (i, ii,\\nand iii):  \\ni. Patient is ‚â• 2 years of age; AND  \\nii. Patient meets ONE of the following (a, b, c, or d):\\na) Patient has tried one other systemic therapy for this condition; OR\\nNote: Examples of other systemic therapies for JIA include methotrexate,\\nsulfasalazine, leflunomide, or a nonsteroidal anti-inflammatory drug (NSAID)\\n[e.g., ibuprofen, naproxen]. A previous trial of one biologic other than the\\nrequested medication also counts as a trial of one systemic therapy for JIA. A\\nbiosimilar of the requested biologic does not count. Refer to Appendix for\\nexamples of biologics used for JIA.  \\nb) Patient will be starting on adalimumab concurrently with methotrexate,\\nsulfasalazine, or leflunomide; OR  \\nc) Patient has an absolute contraindication to methotrexate, sulfasalazine, or\\nleflunomide; OR\\nNote: Examples of contraindications to methotrexate include pregnancy,\\nbreast feeding, alcoholic liver disease, immunodeficiency syndrome, blood\\ndyscrasias.  \\nd) Patient has aggressive disease, as determined by the prescriber; AND\\niii. The medication is prescribed by or in consultation with a rheumatologist.  \\nB) Patient is Currently Receiving an Adalimumab Product. Approve for 1 year if the\\npatient meets BOTH of the following (i and ii):  \\ni. Patient has been established on therapy for at least 6 months; AND\\nNote: A patient who has received < 6 months of therapy or who is restarting\\ntherapy with an adalimumab product is reviewed under criterion A (Initial\\nTherapy).  \\n3 Pages - Cigna National Formulary Coverage - Policy:Inflammatory Conditions - Adalimumab Products Prior\\nAuthorization Policy  \\n<!-- PageBreak -->  \\nii. Patient meets at least ONE of the following (a or b):  \\na) When assessed by at least one objective measure, patient experienced a\\nbeneficial clinical response from baseline (prior to initiating an adalimumab\\nproduct); OR  \\nNote: Examples of objective measures include Physician Global Assessment\\n(MD global), Parent/Patient Global Assessment of Overall Well-Being (PGA),\\nParent/Patient Global Assessment of Disease Activity (PDA), Juvenile Arthritis\\nDisease Activity Score (JDAS), Clinical Juvenile Arthritis Disease Activity Score\\n(cJDAS), Juvenile Spondyloarthritis Disease Activity Index (JSpADA), serum\\nmarkers (e.g., C-reactive protein, erythrocyte sedimentation rate), and/or\\nreduced dosage of corticosteroids.  \\nb) Compared with baseline (prior to initiating an adalimumab product), patient\\nexperienced an improvement in at least one symptom, such as improvement\\nin limitation of motion, less joint pain or tenderness, decreased duration of\\nmorning stiffness or fatigue, or improved function or activities of daily living.  \\n4\\\\. Hidradenitis Suppurativa. Approve for the duration noted if the patient meets ONE of\\nthe following (A or B):  \\nA) Initial Therapy. Approve for 3 months if the patients meets ALL of the following (i, ii,\\nand iii):  \\ni. Patient is ‚â• 12 years of age; AND  \\nii. Patient has tried at least ONE other therapy; AND  \\nNote: Examples include intralesional or oral corticosteroids (such as\\ntriamcinolone or prednisone), systemic antibiotics (e.g., clindamycin, dicloxacillin,\\nor erythromycin), or isotretinoin.  \\niii. The medication is prescribed by or in consultation with a dermatologist.  \\nB) Patient is Currently Receiving an Adalimumab Product. Approve for 1 year if the\\npatient meets ALL of the following (i, ii, and iii):  \\ni. Patient has been established on therapy for at least 3 months; AND\\nNote: A patient who has received < 3 months of therapy or who is restarting\\ntherapy with an adalimumab product is reviewed under criterion A (Initial\\nTherapy).  \\nii. When assessed by at least one objective measure, patient experienced a\\nbeneficial clinical response from baseline (prior to initiating an adalimumab\\nproduct); AND  \\nNote: Examples of objective measures include Hurley staging, Sartorius score,\\nPhysician Global Assessment, and Hidradenitis Suppurativa Severity Index.  \\niii. Compared with baseline (prior to initiating an adalimumab product), patient\\nexperienced an improvement in at least one symptom, such as decreased pain or\\ndrainage of lesions, nodules, or cysts.  \\n5\\\\. Plaque Psoriasis. Approve for the duration noted if the patient meets ONE of the\\nfollowing (A or B):  \\nA) Initial Therapy. Approve for 3 months if the patient meets ALL of the following (i, ii,  \\nand iii):  \\ni. Patient is ‚â• 18 years of age; AND  \\nii. Patient meets ONE of the following (a or b):  \\na) Patient has tried at least one traditional systemic agent for psoriasis for at\\nleast 3 months, unless intolerant; OR  \\nNote: Examples include methotrexate, cyclosporine, or acitretin. A 3-month\\ntrial of psoralen plus ultraviolet A light (PUVA) also counts. An exception to\\nthe requirement for a trial of one traditional systemic agent for psoriasis can\\nbe made if the patient has already had a 3-month trial or previous intolerance  \\n3 Pages - Cigna National Formulary Coverage - Policy:Inflammatory Conditions - Adalimumab Products Prior\\nAuthorization Policy  \\n<!-- PageBreak -->  \\nto at least one biologic other than the requested medication. A biosimilar of\\nthe requested biologic does not count. Refer to Appendix for examples of\\nbiologics used for psoriasis. A patient who has already tried a biologic for\\npsoriasis is not required to \"step back\" and try a traditional systemic agent for\\npsoriasis.  \\nb) Patient has a contraindication to methotrexate, as determined by the\\nprescriber; AND  \\niii. The medication is prescribed by or in consultation with a dermatologist.  \\nB) Patient is Currently Receiving an Adalimumab Product. Approve for 1 year if the\\npatient meets ALL of the following (i, ii, and iii):  \\ni. Patient has been established on therapy for at least 3 months; AND\\nNote: A patient who has received < 3 months of therapy or who is restarting\\ntherapy with an adalimumab product is reviewed under criterion A (Initial\\nTherapy).  \\nii. Patient experienced a beneficial clinical response, defined as improvement from\\nbaseline (prior to initiating an adalimumab product) in at least one of the\\nfollowing: estimated body surface area affected, erythema, induration/thickness,\\nand/or scale of areas affected by psoriasis; AND  \\niii. Compared with baseline (prior to receiving an adalimumab product), patient\\nexperienced an improvement in at least one symptom, such as decreased pain,\\nitching, and/or burning.  \\n6\\\\. Psoriatic Arthritis. Approve for the duration noted if the patient meets ONE of the\\nfollowing (A or B):  \\nA) Initial Therapy. Approve for 6 months if the patient meets BOTH of the following (i\\nand ii):  \\ni. Patient is ‚â• 18 years of age; AND  \\nii. The medication is prescribed by or in consultation with a rheumatologist or a\\ndermatologist.  \\nB) Patient is Currently Receiving an Adalimumab Product. Approve for 1 year if the\\npatient meets BOTH of the following (i and ii):  \\ni. Patient has been established on therapy for at least 6 months; AND\\nNote: A patient who has received < 6 months of therapy or who is restarting\\ntherapy with an adalimumab product is reviewed under criterion A (Initial\\nTherapy).  \\nii. Patient meets at least ONE of the following (a or b):  \\na) When assessed by at least one objective measure, patient experienced a\\nbeneficial clinical response from baseline (prior to initiating an adalimumab\\nproduct); OR\\nNote: Examples of objective measures of disease activity include Disease\\nActivity Index for Psoriatic Arthritis (DAPSA), Composite Psoriatic Disease\\nActivity Index (CPDAI), Psoriatic Arthritis Disease Activity Score (PsA DAS),\\nGrace Index, Leeds Enthesitis Score (LEI), Spondyloarthritis Consortium of\\nCanada (SPARCC) enthesitis score, Leeds Dactylitis Instrument Score,\\nMinimal Disease Activity (MDA), Psoriatic Arthritis Impact of Disease (PsAID-\\n12), and/or serum markers (e.g., C-reactive protein, erythrocyte\\nsedimentation rate).  \\nb) Compared with baseline (prior to initiating an adalimumab product), patient\\nexperienced an improvement in at least one symptom, such as less joint pain,\\nmorning stiffness, or fatigue; improved function or activities of daily living; or\\ndecreased soft tissue swelling in joints or tendon sheaths.  \\n<!-- PageFooter=\"3 Pages - Cigna National Formulary Coverage - Policy:Inflammatory Conditions - Adalimumab Products Prior Authorization Policy\" -->\\n<!-- PageBreak -->  \\n7\\\\. Rheumatoid Arthritis. Approve for the duration noted if the patient meets ONE of the\\nfollowing (A or B):  \\nA) Initial Therapy. Approve for 6 months if the patient meets ALL of the following (i, ii,\\nand iii):  \\ni. Patient is ‚â• 18 years of age; AND  \\nii. Patient has tried ONE conventional synthetic disease-modifying antirheumatic\\ndrug (DMARD) for at least 3 months; AND  \\nNote: Examples include methotrexate (oral or injectable), leflunomide,\\nhydroxychloroquine, and sulfasalazine. An exception to the requirement for a trial\\nof one conventional synthetic DMARD can be made if the patient has already had\\na 3-month trial with at least one biologic other than the requested medication. A\\nbiosimilar of the requested biologic does not count. Refer to Appendix for\\nexamples of biologics used for rheumatoid arthritis. A patient who has already\\ntried a biologic for rheumatoid arthritis is not required to \"step back\" and try a\\nconventional synthetic DMARD.  \\nii. The medication is prescribed by or in consultation with a rheumatologist.  \\nB) Patient is Currently Receiving an Adalimumab Product. Approve for 1 year if the\\npatient meets BOTH of the following (i and ii):  \\ni. Patient has been established on therapy for at least 6 months; AND\\nNote: A patient who has received < 6 months of therapy or who is restarting\\ntherapy with an adalimumab product is reviewed under criterion A (Initial\\nTherapy).  \\nii. Patient meets at least ONE of the following (a or b):  \\na) Patient experienced a beneficial clinical response when assessed by at least\\none objective measure; OR\\nNote: Examples of objective measures of disease activity include Clinical\\nDisease Activity Index (CDAI), Disease Activity Score (DAS) 28 using\\nerythrocyte sedimentation rate or C-reactive protein, Patient Activity Scale\\n(PAS)-II, Rapid Assessment of Patient Index Data 3 (RAPID-3), and/or\\nSimplified Disease Activity Index (SDAI).  \\nb) Patient experienced an improvement in at least one symptom, such as\\ndecreased joint pain, morning stiffness, or fatigue; improved function or\\nactivities of daily living; or decreased soft tissue swelling in joints or tendon\\nsheaths.  \\n8\\\\. Ulcerative Colitis. Approve for the duration noted if the patient meets ONE of the\\nfollowing (A or B):  \\nA) Initial Therapy. Approve for 6 months if the patient meets ALL of the following (i, ii,\\nand iii):  \\ni. Patient is ‚â• 5 years of age; AND  \\nii. Patient meets ONE of the following (a or b):\\na) Patient has tried one systemic therapy; OR  \\nNote: Examples include 6-mercaptopurine, azathioprine, cyclosporine,\\ntacrolimus, or a corticosteroid such as prednisone or methylprednisolone. A\\ntrial of one biologic other than the requested medication also counts as a trial\\nof one systemic agent for ulcerative colitis. A biosimilar of the requested\\nbiologic does not count. Refer to Appendix for examples of biologics used for\\nulcerative colitis.  \\nb) Patient meets BOTH of the following [(1) and (2)]:  \\n(1)Patient has pouchitis; AND\\n(2)Patient has tried an antibiotic, probiotic, corticosteroid enema, or\\nmesalamine enema; AND  \\n3 Pages - Cigna National Formulary Coverage - Policy:Inflammatory Conditions - Adalimumab Products Prior\\nAuthorization Policy  \\n<!-- PageBreak -->  \\nNote: Examples of antibiotics include metronidazole and ciprofloxacin.\\nExamples of corticosteroid enemas include hydrocortisone enema.  \\niii. The medication is prescribed by or in consultation with a gastroenterologist.  \\nB) Patient is Currently Receiving an Adalimumab Product. Approve for 1 year if the\\npatient meets BOTH of the following (i and ii):  \\ni. Patient has been established on therapy for at least 6 months; AND\\nNote: A patient who has received < 6 months of therapy or who is restarting\\ntherapy with an adalimumab product is reviewed under criterion A (Initial\\nTherapy).  \\nii. Patient meets at least ONE of the following (a or b):  \\na) When assessed by at least one objective measure, patient experienced a\\nbeneficial clinical response from baseline (prior to initiating an adalimumab\\nproduct); OR\\nNote: Examples of objective measures include fecal markers (e.g., fecal\\ncalprotectin), serum markers (e.g., C-reactive protein), endoscopic\\nassessment, and/or reduced dose of corticosteroids.  \\nb) Compared with baseline (prior to initiating an adalimumab product), patient\\nexperienced an improvement in at least one symptom, such as decreased\\npain, fatigue, stool frequency, and/or rectal bleeding.  \\n9\\\\. Uveitis (including other posterior uveitides and panuveitis syndromes). Approve\\nfor the duration noted if the patient meets ONE of the following (A or B):  \\nA) Initial Therapy. Approve for 6 months if the patient meets ALL of the following (i, ii,\\nand iii):  \\ni. Patient is ‚â• 2 years of age; AND  \\nii. Patient has tried ONE of the following therapies: periocular, intraocular, or\\nsystemic corticosteroids; immunosuppressives; AND\\nNote: Examples of corticosteroids include prednisolone, triamcinolone,\\nbetamethasone, methylprednisolone, and prednisone. Examples of\\nimmunosuppressive agents include methotrexate, mycophenolate mofetil,\\nazathioprine, and cyclosporine. A trial of one biologic other than the requested\\nmedication also counts. A biosimilar of the requested biologic does not count.  \\niii. The medication is prescribed by or in consultation with an ophthalmologist.  \\nB) Patient is Currently Receiving an Adalimumab Product. Approve for 1 year if the\\npatient meets BOTH of the following (i and ii):  \\ni. Patient has been established on therapy for at least 6 months; AND\\nNote: A patient who has received < 6 months of therapy or who is restarting\\ntherapy with an adalimumab product is reviewed under criterion A (Initial\\nTherapy).  \\nii. Patient meets at least one of the following (a or b):  \\na) When assessed by at least one objective measure, patient experienced a\\nbeneficial clinical response from baseline (prior to initiating an adalimumab\\nproduct); OR  \\nNote: Examples of objective measures include best-corrected visual acuity,\\nassessment of chorioretinal and/or inflammatory retinal vascular lesions, or\\nanterior chamber cell grade or vitreous haze grade.  \\nb) Compared with baseline (prior to initiating an adalimumab product), patient\\nexperienced an improvement in at least one symptom, such as decreased eye\\npain, redness, light sensitivity, and/or blurred vision; or improvement in\\nvisual acuity.'),\n",
       " Document(metadata={'Header 1': 'Other Uses with Supportive Evidence'}, page_content='3 Pages - Cigna National Formulary Coverage - Policy:Inflammatory Conditions - Adalimumab Products Prior\\nAuthorization Policy  \\n<!-- PageBreak -->  \\n10\\\\. Behcet\\'s Disease. Approve for the duration noted if the patient meets ONE of the\\nfollowing (A or B):  \\nA) Initial Therapy. Approve for 3 months if the patient meets ALL of the following (i, ii,\\nand ii):  \\ni. Patient is > 2 years of age; AND  \\nii. Patient meets ONE of the following (a or b):\\na) Patient has tried at least ONE conventional therapy; OR\\nNote: Examples include systemic corticosteroids (e.g., methylprednisolone),\\nimmunosuppressants (e.g., azathioprine, methotrexate, mycophenolate\\nmofetil, cyclosporine, tacrolimus, Leukeran [chlorambucil tablets],\\ncyclophosphamide, interferon alfa). A trial of one biologic other than the\\nrequested medication also counts. A patient who has already tried one\\nbiologic other than the requested drug for Behcet\\'s disease is not required to\\n\"step back\" and try a conventional therapy. A biosimilar of the requested\\nbiologic does not count.  \\nb) Patient has ophthalmic manifestations of Behcet\\'s disease; AND  \\niii. The medication is prescribed by or in consultation with a rheumatologist,\\ndermatologist, ophthalmologist, gastroenterologist, or neurologist.  \\nB) Patient is Currently Receiving an Adalimumab Product. Approve for 1 year if the\\npatient meets ALL of the following (i, ii, and iii):  \\ni. Patient has been established on therapy for at least 3 months; AND\\nNote: A patient who has received < 3 months of therapy or who is restarting\\ntherapy with an adalimumab product is reviewed under criterion A (Initial\\nTherapy).  \\nii. When assessed by at least one objective measure, patient experienced a\\nbeneficial clinical response from baseline (prior to initiating an adalimumab\\nproduct); AND  \\nNote: Examples of objective measures are dependent upon organ involvement\\nbut may include best-corrected visual acuity (if ophthalmic manifestations);\\nserum markers (e.g., C-reactive protein, erythrocyte sedimentation rate); or\\nulcer depth, number, and/or lesion size.  \\niii. Compared with baseline (prior to initiating an adalimumab product), patient\\nexperienced an improvement in at least one symptom, such as decreased pain or\\nimproved visual acuity (if ophthalmic manifestations).  \\n11\\\\. Pyoderma Gangrenosum. Approve for the duration noted if the patient meets ONE of\\nthe following (A or B):  \\nA) Initial Therapy. Approve for 4 months if the patient meets ALL of the following (i, ii,\\nand iii):  \\ni. Patient is > 18 years of age; AND  \\nii. Patient meets ONE of the following (a or b):  \\na) Patient has tried one systemic corticosteroid; OR\\nNote: An example is prednisone.  \\nb) Patient has tried one other immunosuppressant for at least 2 months or was\\nintolerant to one of these agents; AND\\nNote: Examples include mycophenolate mofetil and cyclosporine.  \\niii. The medication is prescribed by or in consultation with a dermatologist.  \\nB) Patient is Currently Receiving an Adalimumab Product. Approve for 1 year if the\\npatient meets ALL of the following (i, ii, and iii):  \\ni. Patient has been established on therapy for at least 4 months; AND\\nNote: A patient who has received < 4 months of therapy or who is restarting\\ntherapy with an adalimumab product is reviewed under criterion A (Initial\\nTherapy).  \\n3 Pages - Cigna National Formulary Coverage - Policy:Inflammatory Conditions - Adalimumab Products Prior\\nAuthorization Policy  \\n<!-- PageBreak -->  \\nii. Patient experienced a beneficial clinical response, defined as improvement from\\nbaseline (prior to initiating an adalimumab product) in at least one of the\\nfollowing: size, depth, and/or number of lesions; AND  \\niii. Compared with baseline (prior to initiating an adalimumab product), patient\\nexperienced an improvement in at least one symptom, such as decreased pain\\nand/or tenderness of affected lesions.  \\n12\\\\. Sarcoidosis. Approve for the duration noted if the patient meets ONE of the following\\n(A or B):  \\nA) Initial Therapy. Approve for 3 months if the patient meets ALL of the following (i, ii,\\niii, and iv):  \\ni. Patient is > 18 years of age; AND  \\nii. Patient has tried at least one corticosteroid; AND\\nNote: An example is prednisone.  \\niii. Patient has tried at least one immunosuppressive medication; AND\\nNote: Examples include methotrexate, leflunomide, azathioprine, mycophenolate\\nmofetil, cyclosporine, Leukeran (chlorambucil tablets), cyclophosphamide,\\nThalomid (thalidomide capsules), an infliximab product, or chloroquine.  \\niv. The medication is prescribed by or in consultation with a pulmonologist,\\nophthalmologist, or dermatologist.  \\nB) Patient is Currently Receiving an Adalimumab Product. Approve for 1 year if the\\npatient meets ALL of the following (i, ii, and iii):  \\ni. Patient has been established on therapy for at least 3 months; AND\\nNote: A patient who has received < 3 months of therapy or who is restarting\\ntherapy with an adalimumab product is reviewed under criterion A (Initial\\nTherapy).  \\nii. When assessed by at least one objective measure, patient experienced a\\nbeneficial clinical response from baseline (prior to initiating an adalimumab\\nproduct); AND  \\nNote: Examples of objective measures are dependent upon organ involvement\\nbut may include lung function (e.g., predicted forced vital capacity and/or 6-\\nminute walk distance); serum markers (e.g., C-reactive protein, liver enzymes,\\nN-terminal pro-brain natriuretic peptide [NT-proBNP]); improvement in rash or\\nskin manifestations, neurologic symptoms, or rhythm control; or imaging (e.g., if\\nindicated, chest radiograph, magnetic resonance imaging [MRI], or\\nechocardiography).  \\niii. Compared with baseline (prior to initiating an adalimumab product), patient\\nexperienced an improvement in at least one symptom, such as decreased cough,\\nfatigue, pain, palpitations, neurologic symptoms, and/or shortness of breath.  \\n13\\\\. Scleritis or Sterile Corneal Ulceration. Approve for the duration noted if the patient\\nmeets ONE of the following (A or B):  \\nA) Initial Therapy. Approve for 6 months if the patient meets ALL of the following (i, ii,\\nand iii):  \\ni. Patient is > 18 years of age; AND  \\nii. Patient has tried one other therapy for this condition; AND  \\nNote: Examples include oral nonsteroidal anti-inflammatory drugs (NSAIDs) such\\nas indomethacin, naproxen, or ibuprofen; oral, topical (ophthalmic), or\\nintravenous corticosteroids (such as prednisone, prednisolone,\\nmethylprednisolone); methotrexate; cyclosporine; or other immunosupressants.\\niii. The medication is prescribed by or in consultation with an ophthalmologist.  \\nB) Patient is Currently Receiving an Adalimumab Product. Approve for 1 year if the\\npatient meets BOTH of the following (i and ii):  \\n3 Pages - Cigna National Formulary Coverage - Policy:Inflammatory Conditions - Adalimumab Products Prior\\nAuthorization Policy  \\n<!-- PageBreak -->  \\ni. Patient has been established on therapy for at least 6 months; AND  \\nNote: A patient who has received < 6 months of therapy or who is restarting\\ntherapy with an adalimumab product is reviewed under criterion A (Initial\\nTherapy).  \\nii. Patient meets at least ONE of the following (a or b):  \\na) When assessed by at least one objective measure, patient experienced a\\nbeneficial clinical response from baseline (prior to initiating an adalimumab\\nproduct); OR  \\nNote: Examples of objective measures are serum markers (e.g., C-reactive\\nprotein, erythrocyte sedimentation rate).  \\nb) Compared with baseline (prior to initiating an adalimumab product), patient\\nexperienced an improvement in at least one symptom, such as decreased eye\\npain, redness, light sensitivity, tearing, and/or improvement in visual acuity.  \\n14\\\\. Spondyloarthritis, Other Subtypes. Approve for the duration noted if the patient\\nmeets ONE of the following (A or B):  \\nNote: This includes undifferentiated arthritis, non-radiographic axial spondyloarthritis,\\nreactive arthritis (Reiter\\'s disease), or arthritis associated with inflammatory bowel\\ndisease. For ankylosing spondylitis or psoriatic arthritis, refer to the respective criteria\\nunder FDA-approved indications.  \\nA) Initial Therapy. Approve for 6 months if the patient meets ALL of the following (i, ii,\\nand iii):  \\ni. Patient is > 18 years of age; AND  \\nii. Patient meets ONE of the following (a or b):  \\na) Patient meets BOTH of the following [(1) and (2)]:  \\n(1)Patient has arthritis primarily in the knees, ankles, elbows, wrists, hands,\\nand/or feet; AND  \\n(2)Patient has tried at least one conventional synthetic disease-modifying\\nantirheumatic drug (DMARD); OR  \\nNote: Examples include methotrexate, leflunomide, or sulfasalazine.  \\nb) Patient has axial spondyloarthritis AND has objective signs of inflammation,\\ndefined as at least ONE of the following [(1) or (2)]:  \\n(1)C-reactive protein elevated beyond the upper limit of normal for the\\nreporting laboratory; OR  \\n(2)Sacroiliitis reported on magnetic resonance imaging (MRI); AND  \\niii. The medication is prescribed by or in consultation with a rheumatologist.  \\nB) Patient is Currently Receiving an Adalimumab Product. Approve for 1 year if the\\npatient meets BOTH of the following (i and ii):  \\ni. Patient has been established on therapy for at least 6 months; AND\\nNote: A patient who has received < 6 months of therapy or who is restarting\\ntherapy with an adalimumab product is reviewed under criterion A (Initial\\nTherapy).  \\nii. Patient meets at least ONE of the following (a or b):  \\na) When assessed by at least one objective measure, patient experienced a\\nbeneficial clinical response from baseline (prior to initiating an adalimumab\\nproduct); OR  \\nNote: Examples of objective measures include Ankylosing Spondylitis Disease\\nActivity Score (ASDAS) and/or serum markers (e.g., C-reactive protein,\\nerythrocyte sedimentation rate).  \\nb) Compared with baseline (prior to initiating an adalimumab product),\\npatient experienced an improvement in at least one symptom, s  \\nc) Abrilada‚Ñ¢ (adalimumab-afzb subcutaneous injection - Pfizer)  \\nd) adalimumab-aacf subcutaneous injection (Fresenius Kabi)  \\n3 Pages - Cigna National Formulary Coverage - Policy:Inflammatory Conditions - Adalimumab Products Prior\\nAuthorization Policy  \\n<!-- PageBreak -->  \\ne) adalimumab-adaz subcutaneous injection (Sandoz/Novartis)  \\nf) adalimumab-adbm subcutaneous injection (Boehringer Ingelheim)  \\ng) adalimumab-fkjp subcutaneous injection (Mylan)  \\nh) adalimumab-ryvk subcutaneous injection (Teva/Alvotech)  \\ni) Amjevita (adalimumab-atto subcutaneous injection - Amgen)  \\nj) Cyltezo¬Æ (adalimumab-adbm subcutaneous injection - Boehringer Ingelheim)  \\nk) Hadlima‚Ñ¢ (adalimumab-bwwd subcutaneous injection - Organon/Samsung\\nBioepis)  \\n1\\\\) Hulio¬Æ (adalimumab-fkjp subcutaneous injection - Mylan)  \\nm) Humira¬Æ (adalimumab subcutaneous injection - AbbVie, Cordavis)  \\nn) Hyrimoz¬Æ (adalimumab-adaz subcutaneous injection - Sandoz/Novartis,\\nCordavis)  \\no) Idacio¬Æ (adalimumab-aacf subcutaneous injection - Fresenius Kabi)  \\np) Simlandi¬Æ (adalimumab-ryvk subcutaneous injection - Teva/Alvotech)  \\nq) Yuflyma¬Æ (adalimumab-aaty subcutaneous injection - Celltrion)  \\nr) Yusimry‚Ñ¢ (adalimuamb-aqvh subcutaneous injection - Coherus)  \\ns) is(are) considered experimental, investigational, or unproven for ANY other\\nuse(s) including the following (this list may not be all inclusive; criteria will be\\nupdated as new published data are available):  \\nt) uch as decreased pain or stiffness, or improvement in function or activities of\\ndaily living.'),\n",
       " Document(metadata={'Header 1': 'CONDITIONS NOT COVERED'}, page_content=\"1\\\\. Concurrent Use with a Biologic or with a Targeted Synthetic Oral Small\\nMolecule Drug. This medication should not be administered in combination with\\nanother biologic or with a targeted synthetic oral small molecule drug used for an\\ninflammatory condition (see Appendix for examples). Combination therapy is generally\\nnot recommended due to a potentially higher rate of adverse events and lack of\\ncontrolled clinical data supporting additive efficacy.  \\nNote: This does NOT exclude the use of conventional synthetic DMARDs (e.g.,\\nmethotrexate, leflunomide, hydroxychloroquine, or sulfasalazine) in combination with\\nthis medication.  \\n2\\\\. Polymyalgia Rheumatica (PMR). EULAR/ACR guidelines for the management of PMR\\n(2015) strongly recommend against the use of TNFis for treatment of PMR.17 This\\nrecommendation is based on lack of evidence for benefit as well as considerable\\npotential for harm.  \\nREFERENCES  \\n1\\\\. Humira¬Æ subcutaneous injection [prescribing information]. North Chicago, IL: AbbVie;\\nOctober 2023.  \\n2\\\\. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology\\nGuideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1-\\n26\\\\.  \\n3\\\\. Ward MM, Deodhar A, Gensler LS, et al. 2019 update of the American College of\\nRheumatology/Spondylitis Association of America/Spondyloarthritis Research and\\nTreatment Network recommendations for the treatment of ankylosing spondylitis and\\nnonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599-1613.  \\n4\\\\. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG Clinical Guideline: Management of\\nCrohn's Disease in Adults. Am J Gastroenterol. 2018; 113(4):481-517.  \\n5\\\\. Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of\\nRheumatology/Arthritis Foundation Guideline for the treatment of juvenile idiopathic  \\n3 Pages - Cigna National Formulary Coverage - Policy:Inflammatory Conditions - Adalimumab Products Prior\\nAuthorization Policy  \\n<!-- PageBreak -->  \\narthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and\\nenthesitis. Arthritis Rheumatol. 2019;71(6):846-863.  \\n6\\\\. Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology guideline\\nfor the treatment of juvenile idiopathic arthritis: therapeutic approaches for\\noligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic\\narthritis. Arthritis Rheumatol. 2022;74(4):553-569.  \\n7\\\\. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the\\nmanagement and treatment of psoriasis with biologics. J Am Acad Dermatol.\\n2019;80(4):1029-1072.  \\n8\\\\. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology\\nguideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol.\\n2021;73(7):1108-1123.  \\n9\\\\. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis\\nin adults. Am J Gastroenterol. 2019;114(3):384-413.  \\n10\\\\. Feuerstein JD, Isaac s KL, Schneider Y, et al. AGA clinical practice guidelines on the\\nmanagement of moderate to severe ulcerative colitis. Gastroenterology. 2020;\\n158:1450-1461.  \\n11\\\\. Pardi DS, D'Haens G, Shen B, et al. Clinical guidelines for the management of pouchitis.\\nInflamm Bowel Dis. 2009;15(9):1424-1431.  \\n12\\\\. Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of\\nanti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.\\nOphthalmology. 2014;121(3):785-796.  \\n13\\\\. Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for\\nthe management of Behcet's syndrome. Ann Rheum Dis. 2018;77(6):808-818.  \\n14\\\\. Dabade TS, Davis MD. Diagnosis, and treatment of the neutrophilic dermatoses\\n(pyoderma gangrenosum, Sweet's syndrome). Dermatol Ther. 2011;24(2):273-284.  \\n15\\\\. Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment\\nof sarcoidosis. Eur Respir J. 2021;58(6):2004079.  \\n16\\\\. Dejaco C, Singh YP, Perel P, et al. 2015 Recommendations for the management of\\npolymyalgia rheumatica: a European League Against Rheumatism/American College of\\nRheumatology Collaborative Initiative. Arthritis Rheumatol. 2015;67(10):2569-2580.  \\n17\\\\. Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical practice guidelines on the medical\\nmanagement of moderate to severe luminal and perianal fistulizing Crohn's disease.\\nGastroenterology. 2021;160(7):2496-2508.  \\n18\\\\. Angeles-Han ST, Ringold S, Beukelman T, et al. 2019 American College of\\nRheumatology/Arthritis Foundation guideline for the screening, monitoring, and\\ntreatment of juvenile idiopathic arthritis-associated uveitis. Arthritis Rheumatol.\\n2019;71(6):864-877.  \\n19\\\\. Ingram JR, Collier F, Brown D, et al. British Association of Dermatologists guidelines for\\nthe management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol.\\n2019;180(5):1009-1017.\"),\n",
       " Document(metadata={'Header 1': 'CONDITIONS NOT COVERED', 'Header 2': 'HISTORY'}, page_content=\"<table>\\n<tr>\\n<th>Type of Revision</th>\\n<th>Summary of Changes</th>\\n<th>Review Date</th>\\n</tr>\\n<tr>\\n<td>Annual Revision</td>\\n<td>No criteria changes.</td>\\n<td>04/05/2023</td>\\n</tr>\\n<tr>\\n<td>Selected Revision</td>\\n<td>The following biosimilars were added to the policy: Abrilada, adalimumab-adaz, adalimumab-fkjp, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yuflyma, and Yusimry. The criteria for these biosimilars are that same as the existing criteria for Adalimumab Products. There were no other changes to the criteria.</td>\\n<td>07/05/2023</td>\\n</tr>\\n</table>  \\n3 Pages - Cigna National Formulary Coverage - Policy:Inflammatory Conditions - Adalimumab Products Prior\\nAuthorization Policy  \\n<!-- PageBreak -->  \\n<table>\\n<tr>\\n<td>Annual Revision</td>\\n<td>Plaque Psoriasis: For a patient currently taking an adalimumab product, the timeframe for established on therapy was changed from 90 days to 3 months. Behcet's Disease: For a patient currently taking an adalimumab product, the timeframe for established on therapy was changed from 90 days to 3 months. Hidradenitis Suppurativa: For a patient currently taking an adalimumab product, the timeframe for established on therapy was changed from 90 days to 3 months. Sarcoidosis: For a patient currently taking an adalimumab product, the timeframe for established on therapy was changed from 90 days to 3 months.</td>\\n<td>03/27/2024</td>\\n</tr>\\n<tr>\\n<td>Selected Revision</td>\\n<td>Simlandi was added to the policy. The criteria for Simlandi are the same as the existing criteria for other adalimumab products. There are no other changes to the criteria.</td>\\n<td>04/03/2024</td>\\n</tr>\\n<tr>\\n<td>Selected Revision</td>\\n<td>Adalimumab-aacf and adalimumab-ryvk were added to the policy. The criteria are the same as the existing criteria for other adalimumab products. The following changes were also made: Ankylosing Spondylitis: For initial approvals, a requirement that the patient is ‚â• 18 years of age was added. Hidradenitis Suppurativa: For initial approvals, a requirement that the patient is ‚â• 12 years of age was added. Juvenile Idiopathic Arthritis: For initial approvals, a requirement that the patient is ‚â• 2 years of age was added. Plaque Psoriasis: In the Note, psoralen plus ultraviolet A light (PUVA) was removed from the examples of traditional systemic therapies. An additional Note was added that a 3-month trial of PUVA counts as a traditional systemic therapy. Psoriatic Arthritis: For initial approvals, a requirement that the patient is ‚â• 18 years of age was added. Rheumatoid Arthritis: For initial approvals, a requirement that the patient is ‚â• 18 years of age was added. Uveitis: For initial approvals, a requirement that the patient is ‚â• 2 years of age was added. Behcet's Disease: For initial approvals, a requirement that the patient is ‚â• 2 years of age was added. Pyoderma Gangrenosum: For initial approvals, a requirement that the patient is ‚â• 18 years of age was added. Sarcoidosis: For initial approvals, a requirement that the patient is ‚â• 18 years of age was added. Scleritis or Sterile Corneal Ulceration: For initial approvals, a requirement that the patient is ‚â• 18 years of age was added. Spondyloarthritis, Other Subtypes: For initial approvals, a requirement that the patient is ‚â• 18 years of age was added. Conditions Not Covered : Concurrent use with a Biologic or with a Targeted Synthetic Oral Small Molecule Drug was changed to as listed (previously oral small molecule drug was listed as Disease-Modifying Antirheumatic Drug).</td>\\n<td>09/11/2024</td>\\n</tr>\\n</table>\"),\n",
       " Document(metadata={'Header 1': 'CONDITIONS NOT COVERED', 'Header 2': 'HISTORY', 'Header 3': 'APPENDIX'}, page_content='<table>\\n<tr>\\n<th>Mechanism of</th>\\n<th>Examples of</th>\\n</tr>\\n<tr>\\n<td>Action</td>\\n<td>Indications*</td>\\n</tr>\\n</table>  \\n3 Pages - Cigna National Formulary Coverage - Policy:Inflammatory Conditions - Adalimumab Products Prior\\nAuthorization Policy  \\n<!-- PageBreak -->  \\n<table>\\n<tr>\\n<td colspan=\"3\">Biologics</td>\\n</tr>\\n<tr>\\n<td>Adalimumab SC Products (Humira¬Æ, biosimilars)</td>\\n<td>Inhibition of TNF</td>\\n<td>AS, CD, JIA, PsO, PsA, RA, UC</td>\\n</tr>\\n<tr>\\n<td>Cimzia¬Æ (certolizumab pegol SC injection)</td>\\n<td>Inhibition of TNF</td>\\n<td>AS, CD, nr-axSpA, PsO, PSA, RA</td>\\n</tr>\\n<tr>\\n<td>Etanercept SC Products (Enbrel¬Æ, biosimilars)</td>\\n<td>Inhibition of TNF</td>\\n<td>AS, JIA, PsO, PSA, RA</td>\\n</tr>\\n<tr>\\n<td>Infliximab IV Products (Remicade¬Æ, biosimilars)</td>\\n<td>Inhibition of TNF</td>\\n<td>AS, CD, PsO, PsA, RA, UC</td>\\n</tr>\\n<tr>\\n<td>Zymfentra¬Æ (infliximab-dyyb SC injection)</td>\\n<td>Inhibition of TNF</td>\\n<td>CD, UC</td>\\n</tr>\\n<tr>\\n<td rowspan=\"2\">Simponi¬Æ, Simponi Aria¬Æ (golimumab SC injection, golimumab IV infusion)</td>\\n<td rowspan=\"2\">Inhibition of TNF</td>\\n<td>SC formulation: AS, PsA, RA, UC</td>\\n</tr>\\n<tr>\\n<td>IV formulation: AS, PJIA, PSA, RA</td>\\n</tr>\\n<tr>\\n<td rowspan=\"2\">Tocilizumab Products (Actemra¬Æ IV, biosimilar; Actemra SC, biosimilar)</td>\\n<td rowspan=\"2\">Inhibition of IL-6</td>\\n<td>SC formulation: PJIA, RA, SJIA</td>\\n</tr>\\n<tr>\\n<td>IV formulation: PJIA, RA, SJIA</td>\\n</tr>\\n<tr>\\n<td>Kevzara¬Æ (sarilumab SC injection)</td>\\n<td>Inhibition of IL-6</td>\\n<td>RA</td>\\n</tr>\\n<tr>\\n<td rowspan=\"2\">Orencia¬Æ (abatacept IV infusion, abatacept SC injection)</td>\\n<td rowspan=\"2\">T-cell costimulation modulator</td>\\n<td>SC formulation: JIA, PSA, RA</td>\\n</tr>\\n<tr>\\n<td>IV formulation: JIA, PsA, RA</td>\\n</tr>\\n<tr>\\n<td>Rituximab IV Products (Rituxan¬Æ, biosimilars)</td>\\n<td>CD20-directed cytolytic antibody</td>\\n<td>RA</td>\\n</tr>\\n<tr>\\n<td>Kineret¬Æ (anakinra SC injection)</td>\\n<td>Inhibition of IL-1</td>\\n<td>JIA^, RA</td>\\n</tr>\\n<tr>\\n<td>Omvoh¬Æ (mirikizumab IV infusion, SC injection)</td>\\n<td>Inhibition of IL-23</td>\\n<td>UC</td>\\n</tr>\\n<tr>\\n<td rowspan=\"2\">Stelara¬Æ (ustekinumab SC injection, ustekinumab IV infusion)</td>\\n<td rowspan=\"2\">Inhibition of IL- 12/23</td>\\n<td>SC formulation: CD, PsO, PsA, UC</td>\\n</tr>\\n<tr>\\n<td>IV formulation: CD, UC</td>\\n</tr>\\n<tr>\\n<td>Siliq¬Æ (brodalumab SC injection)</td>\\n<td>Inhibition of IL-17</td>\\n<td>PsO</td>\\n</tr>\\n<tr>\\n<td rowspan=\"2\">Cosentyx¬Æ (secukinumab SC injection; secukinumab IV infusion)</td>\\n<td>Inhibition of IL-17A</td>\\n<td>SC formulation: AS, ERA, nr-axSpA, PsO, PsA</td>\\n</tr>\\n<tr>\\n<td></td>\\n<td>IV formulation: AS, nr- axSpA, PsA</td>\\n</tr>\\n<tr>\\n<td>Taltz¬Æ (ixekizumab SC injection)</td>\\n<td>Inhibition of IL-17A</td>\\n<td>AS, nr-axSpA, PsO, PsA</td>\\n</tr>\\n<tr>\\n<td>Bimzelx¬Æ (bimekizumab-bkzx SC injection)</td>\\n<td>Inhibition of IL- 17A/17F</td>\\n<td>PsO</td>\\n</tr>\\n<tr>\\n<td>Ilumya¬Æ (tildrakizumab-asmn SC injection)</td>\\n<td>Inhibition of IL-23</td>\\n<td>PsO</td>\\n</tr>\\n<tr>\\n<td rowspan=\"2\">Skyrizi¬Æ (risankizumab-rzaa SC injection, risankizumab-rzaa IV infusion)</td>\\n<td>Inhibition of IL-23</td>\\n<td>SC formulation: CD, PSA, PsO, UC</td>\\n</tr>\\n<tr>\\n<td></td>\\n<td>IV formulation: CD, UC</td>\\n</tr>\\n<tr>\\n<td rowspan=\"2\">Tremfya¬Æ (guselkumab SC injection, guselkumab IV infusion)</td>\\n<td>Inhibition of IL-23</td>\\n<td>SC formulation: PsA, PsO, UC</td>\\n</tr>\\n<tr>\\n<td></td>\\n<td>IV formulation: UC</td>\\n</tr>\\n<tr>\\n<td>Entyvio¬Æ (vedolizumab IV infusion, vedolizumab SC injection)</td>\\n<td>Integrin receptor antagonist</td>\\n<td>CD, UC</td>\\n</tr>\\n</table>'),\n",
       " Document(metadata={'Header 1': 'CONDITIONS NOT COVERED', 'Header 2': 'APPENDIX (CONTINUED)'}, page_content='3 Pages - Cigna National Formulary Coverage - Policy:Inflammatory Conditions - Adalimumab Products Prior\\nAuthorization Policy  \\n<!-- PageBreak -->  \\n<table>\\n<tr>\\n<th colspan=\"3\">Oral Therapies/Targeted Synthetic Oral Small Molecule Drugs</th>\\n</tr>\\n<tr>\\n<th>Otezla¬Æ (apremilast tablets)</th>\\n<th>Inhibition of PDE4</th>\\n<th>PsO, PsA</th>\\n</tr>\\n<tr>\\n<td>Cibinqo‚Ñ¢ (abrocitinib tablets)</td>\\n<td>Inhibition of JAK pathways</td>\\n<td>AD</td>\\n</tr>\\n<tr>\\n<td>Olumiant¬Æ (baricitinib tablets)</td>\\n<td>Inhibition of JAK pathways</td>\\n<td>RA, AA</td>\\n</tr>\\n<tr>\\n<td>Litfulo¬Æ (ritlecitinib capsules)</td>\\n<td>Inhibition of JAK pathways</td>\\n<td>AA</td>\\n</tr>\\n<tr>\\n<td>Leqselvi¬Æ (deuruxolitinib tablets)</td>\\n<td>Inhibition of JAK pathways</td>\\n<td>AA</td>\\n</tr>\\n<tr>\\n<td>Rinvoq¬Æ (upadacitinib extended- release tablets)</td>\\n<td>Inhibition of JAK pathways</td>\\n<td>AD, AS, nr-axSpA, RA, PsA, UC</td>\\n</tr>\\n<tr>\\n<td>Rinvoq¬Æ LQ (upadacitinib oral solution)</td>\\n<td>Inhibition of JAK pathways</td>\\n<td>PSA, PJIA</td>\\n</tr>\\n<tr>\\n<td>Sotyktu¬Æ (deucravacitinib tablets)</td>\\n<td>Inhibition of TYK2</td>\\n<td>PsO</td>\\n</tr>\\n<tr>\\n<td>Xeljanz¬Æ (tofacitinib tablets/oral solution)</td>\\n<td>Inhibition of JAK pathways</td>\\n<td>RA, PJIA, PsA, UC</td>\\n</tr>\\n<tr>\\n<td>Xeljanz¬Æ XR (tofacitinib extended- release tablets)</td>\\n<td>Inhibition of JAK pathways</td>\\n<td>RA, PsA, UC</td>\\n</tr>\\n<tr>\\n<td>Zeposia¬Æ (ozanimod tablets)</td>\\n<td>Sphingosine 1 phosphate receptor modulator</td>\\n<td>UC</td>\\n</tr>\\n<tr>\\n<td>Velsipity¬Æ (etrasimod tablets)</td>\\n<td>Sphingosine 1 phosphate receptor modulator</td>\\n<td>UC</td>\\n</tr>\\n</table>  \\n\\\\*\\nNot an all-inclusive list of indications. Refer to the prescribing information for the\\nrespective agent for FDA-approved indications; SC - Subcutaneous; TNF - Tumor necrosis\\nfactor; AS - Ankylosing spondylitis; CD - Crohn\\'s disease; JIA - Juvenile idiopathic arthritis;\\nPsO - Plaque psoriasis; PsA - Psoriatic arthritis; RA - Rheumatoid arthritis; UC - Ulcerative\\ncolitis; nr-axSpA - Non-radiographic axial spondyloarthritis; IV - Intravenous, PJIA -\\nPolyarticular juvenile idiopathic arthritis; IL - Interleukin; SJIA - Systemic juvenile\\nidiopathic arthritis; ^ Off-label use of Kineret in JIA supported in guidelines; ERA -\\nEnthesitis-related arthritis; DMARD - Disease-modifying antirheumatic drug; PDE4 -\\nPhosphodiesterase 4; JAK - Janus kinase; AD - Atopic dermatitis; AA - Alopecia areata;\\nTYK2 - Tyrosine kinase 2.  \\n\"Cigna Companies\" refers to operating subsidiaries of The Cigna Group. All products and\\nservices are provided exclusively by or through such operating subsidiaries, including Cigna\\nHealth and Life Insurance Company, Connecticut General Life Insurance Company,\\nEvernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service\\ncompany subsidiaries of The Cigna Group. @ 2024 The Cigna Group.  \\n<!-- PageFooter=\"3 Pages - Cigna National Formulary Coverage - Policy: Inflammatory Conditions - Adalimumab Products Prior Authorization Policy\" -->')]"
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "chunks"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 4. **Vectorize, Add Metadata, Index**"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [],
   "source": [
    "search_client = SearchClient(\n",
    "    endpoint=os.environ[\"AZURE_AI_SEARCH_SERVICE_ENDPOINT\"],\n",
    "    index_name=os.environ[\"AZURE_SEARCH_INDEX_NAME\"],\n",
    "    credential=AzureKeyCredential(os.environ[\"AZURE_SEARCH_ADMIN_KEY\"]),\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "from src.aoai.aoai_helper import AzureOpenAIManager\n",
    "aoai_client = AzureOpenAIManager()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[-0.047314975410699844,\n",
       " 0.012618283741176128,\n",
       " 0.007378609851002693,\n",
       " -0.00984053872525692,\n",
       " 0.028208108618855476,\n",
       " 0.031466756016016006,\n",
       " -0.02137499861419201,\n",
       " 0.0013170961756259203,\n",
       " 0.02908378094434738,\n",
       " 0.03399328514933586]"
      ]
     },
     "execution_count": 35,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "embedding = aoai_client.generate_embedding(input_text=\"perro\")\n",
    "embedding.data[0].embedding[:10] # Display the first 10 dimensions of the embedding"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Total Documents to Upload: 14\n",
      "Uploading batch of 14 documents...\n",
      "Upload of batch of 14 documents succeeded.\n"
     ]
    }
   ],
   "source": [
    "n = 100  # max batch size (number of docs) to upload at a time\n",
    "total_docs_uploaded = 0\n",
    "\n",
    "# Split up a list into chunks\n",
    "def divide_chunks(l, n):\n",
    "    for i in range(0, len(l), n):\n",
    "        yield l[i : i + n]\n",
    "\n",
    "# Generate embeddings (assuming aoai_client is already defined and configured)\n",
    "@retry(wait=wait_random_exponential(min=1, max=20), stop=stop_after_attempt(6))\n",
    "def generate_embeddings(text):\n",
    "    response = aoai_client.generate_embedding(input_text=text)\n",
    "    return response.data[0].embedding\n",
    "\n",
    "# Prepare the data for indexing\n",
    "chunked_content_docs = []\n",
    "\n",
    "for chunk_counter, chunk in enumerate(chunks):\n",
    "    json_data = {\n",
    "        \"parent_id\": \"001\",  # Replace with dynamic Parent ID \n",
    "        \"parent_path\": \"https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/001.pdf\",  # Replace with dynamic Parent Path\n",
    "        \"policy_name\": extract_policy_metadata[\"policy_name\"],\n",
    "        \"payer_name\": extract_policy_metadata[\"payer_name\"],\n",
    "        \"drug_names\": extract_policy_metadata[\"drug_names\"],\n",
    "        \"medical_specialties\": extract_policy_metadata[\"medical_specialties\"],\n",
    "        \"covered_diseases\": extract_policy_metadata[\"indications_diseases\"],\n",
    "        \"covered_diseases_icd_codes\": extract_policy_metadata[\"covered_diseases_icd_codes\"],\n",
    "        \"covered_drug_codes\": extract_policy_metadata[\"covered_drug_codes\"],\n",
    "        \"chunk_id\": f\"001_{chunk_counter}\",  # Ensure unique chunk_id generation\n",
    "        \"chunk\": chunk.page_content,\n",
    "        \"vector\": generate_embeddings(chunk.page_content)\n",
    "    }\n",
    "    chunked_content_docs.append(json_data)\n",
    "\n",
    "total_docs = len(chunked_content_docs)\n",
    "total_docs_uploaded += total_docs\n",
    "print(f\"Total Documents to Upload: {total_docs}\")\n",
    "\n",
    "# Upload chunks to Azure AI Search\n",
    "for documents_chunk in divide_chunks(chunked_content_docs, n):\n",
    "    try:\n",
    "        print(f\"Uploading batch of {len(documents_chunk)} documents...\")\n",
    "        result = search_client.upload_documents(documents=documents_chunk)\n",
    "        if all(res.succeeded for res in result):\n",
    "            print(f\"Upload of batch of {len(documents_chunk)} documents succeeded.\")\n",
    "        else:\n",
    "            print(\"Some documents in the batch were not uploaded successfully.\")\n",
    "    except Exception as ex:\n",
    "        print(\"Error in multiple documents upload: \", ex)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### **Retrieve Data from Azure AI search**"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Before executing this notebook, please review the notebook `03-retrieval.ipynb` for a better understanding of the process. \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "from dotenv import load_dotenv\n",
    "from azure.core.credentials import AzureKeyCredential\n",
    "from azure.search.documents import SearchClient\n",
    "from azure.search.documents.models import (\n",
    "    VectorQuery,\n",
    "    VectorizedQuery,\n",
    "    VectorizableTextQuery,\n",
    "    QueryType,\n",
    "    QueryCaptionType,\n",
    "    QueryAnswerType,\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Set up Azure Cognitive Search credentials\n",
    "service_endpoint = os.getenv(\"AZURE_AI_SEARCH_SERVICE_ENDPOINT\")\n",
    "key = os.getenv(\"AZURE_SEARCH_ADMIN_KEY\")\n",
    "credential = AzureKeyCredential(key)\n",
    "\n",
    "# Define the name of the Azure Search index\n",
    "# This is the index where your data is stored in Azure Search\n",
    "index_name = os.getenv(\"AZURE_SEARCH_INDEX_NAME\")\n",
    "\n",
    "# Set up the Azure Search client with the specified index\n",
    "# This prepares the client to interact with the Azure Search service\n",
    "search_client = SearchClient(service_endpoint, index_name, credential=credential)\n",
    "\n",
    "search_query = \"What is the prior authorization policy for Inflammatory Conditions?\"\n",
    "search_vector = aoai_client.generate_embedding(search_query)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Document Metadata:\n",
      "Parent ID: 001\n",
      "Parent Path: https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/001.pdf\n",
      "Policy Name: Inflammatory Conditions - Adalimumab Products Prior Authorization Policy\n",
      "Payer Name: Cigna\n",
      "Drug Names: ['Abrilada (adalimumab-afzb)', 'adalimumab-aacf', 'adalimumab-adaz', 'adalimumab-adbm', 'adalimumab-fkjp', 'adalimumab-ryvk', 'Humira (adalimumab)', 'Amjevita (adalimumab-atto)', 'Cyltezo (adalimumab-adbm)', 'Hadlima (adalimumab-bwwd)', 'Hulio (adalimumab-fkjp)', 'Hyrimoz (adalimumab-adaz)', 'Idacio (adalimumab-aacf)', 'Simlandi (adalimumab-ryvk)', 'Yuflyma (adalimumab-aaty)', 'Yusimry (adalimumab-aqvh)']\n",
      "Medical Specialties: ['Rheumatology', 'Gastroenterology', 'Dermatology', 'Ophthalmology']\n",
      "Covered Diseases: ['Ankylosing spondylitis', \"Crohn's disease\", 'Hidradenitis suppurativa', 'Juvenile idiopathic arthritis', 'Plaque psoriasis', 'Psoriatic arthritis', 'Rheumatoid arthritis', 'Ulcerative colitis', 'Uveitis', \"Behcet's disease\", 'Pyoderma gangrenosum', 'Sarcoidosis', 'Scleritis', 'Axial spondyloarthritis']\n",
      "Covered Diseases ICD Codes: ['M08.1', 'M45.6', 'M45.2', 'K50.90', 'K50.913', 'K50.914', 'L73.2', 'L40.52', 'M06.9', 'M05.9', 'M06.08', 'K51.80', 'K51.813', 'K51.814', 'H44.133', 'H44.131', 'H44.132', 'M35.2', 'D86.9', 'D86.2', 'D86.0', 'B02.34', 'H15.003', 'H15.013', 'M45.A1', 'M45.A2', 'M45.A3']\n",
      "Covered Drug Codes: ['2640849', '2641642', '2103477', '2640402', '2677776']\n",
      "Chunk ID: 001_2\n",
      "Search Score: 0.02182539738714695\n",
      "Reranker Score: 1.8360580205917358\n",
      "--------------------------------------------------------------------------------\n",
      "Document Metadata:\n",
      "Parent ID: 001\n",
      "Parent Path: https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/001.pdf\n",
      "Policy Name: Inflammatory Conditions - Adalimumab Products Prior Authorization Policy\n",
      "Payer Name: Cigna\n",
      "Drug Names: ['Abrilada (adalimumab-afzb)', 'adalimumab-aacf', 'adalimumab-adaz', 'adalimumab-adbm', 'adalimumab-fkjp', 'adalimumab-ryvk', 'Humira (adalimumab)', 'Amjevita (adalimumab-atto)', 'Cyltezo (adalimumab-adbm)', 'Hadlima (adalimumab-bwwd)', 'Hulio (adalimumab-fkjp)', 'Hyrimoz (adalimumab-adaz)', 'Idacio (adalimumab-aacf)', 'Simlandi (adalimumab-ryvk)', 'Yuflyma (adalimumab-aaty)', 'Yusimry (adalimumab-aqvh)']\n",
      "Medical Specialties: ['Rheumatology', 'Gastroenterology', 'Dermatology', 'Ophthalmology']\n",
      "Covered Diseases: ['Ankylosing spondylitis', \"Crohn's disease\", 'Hidradenitis suppurativa', 'Juvenile idiopathic arthritis', 'Plaque psoriasis', 'Psoriatic arthritis', 'Rheumatoid arthritis', 'Ulcerative colitis', 'Uveitis', \"Behcet's disease\", 'Pyoderma gangrenosum', 'Sarcoidosis', 'Scleritis', 'Axial spondyloarthritis']\n",
      "Covered Diseases ICD Codes: ['M08.1', 'M45.6', 'M45.2', 'K50.90', 'K50.913', 'K50.914', 'L73.2', 'L40.52', 'M06.9', 'M05.9', 'M06.08', 'K51.80', 'K51.813', 'K51.814', 'H44.133', 'H44.131', 'H44.132', 'M35.2', 'D86.9', 'D86.2', 'D86.0', 'B02.34', 'H15.003', 'H15.013', 'M45.A1', 'M45.A2', 'M45.A3']\n",
      "Covered Drug Codes: ['2640849', '2641642', '2103477', '2640402', '2677776']\n",
      "Chunk ID: 001_1\n",
      "Search Score: 0.022482436150312424\n",
      "Reranker Score: 1.8358807563781738\n",
      "--------------------------------------------------------------------------------\n",
      "Document Metadata:\n",
      "Parent ID: 001\n",
      "Parent Path: https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/001.pdf\n",
      "Policy Name: Inflammatory Conditions - Adalimumab Products Prior Authorization Policy\n",
      "Payer Name: Cigna\n",
      "Drug Names: ['Abrilada (adalimumab-afzb)', 'adalimumab-aacf', 'adalimumab-adaz', 'adalimumab-adbm', 'adalimumab-fkjp', 'adalimumab-ryvk', 'Humira (adalimumab)', 'Amjevita (adalimumab-atto)', 'Cyltezo (adalimumab-adbm)', 'Hadlima (adalimumab-bwwd)', 'Hulio (adalimumab-fkjp)', 'Hyrimoz (adalimumab-adaz)', 'Idacio (adalimumab-aacf)', 'Simlandi (adalimumab-ryvk)', 'Yuflyma (adalimumab-aaty)', 'Yusimry (adalimumab-aqvh)']\n",
      "Medical Specialties: ['Rheumatology', 'Gastroenterology', 'Dermatology', 'Ophthalmology']\n",
      "Covered Diseases: ['Ankylosing spondylitis', \"Crohn's disease\", 'Hidradenitis suppurativa', 'Juvenile idiopathic arthritis', 'Plaque psoriasis', 'Psoriatic arthritis', 'Rheumatoid arthritis', 'Ulcerative colitis', 'Uveitis', \"Behcet's disease\", 'Pyoderma gangrenosum', 'Sarcoidosis', 'Scleritis', 'Axial spondyloarthritis']\n",
      "Covered Diseases ICD Codes: ['M08.1', 'M45.6', 'M45.2', 'K50.90', 'K50.913', 'K50.914', 'L73.2', 'L40.52', 'M06.9', 'M05.9', 'M06.08', 'K51.80', 'K51.813', 'K51.814', 'H44.133', 'H44.131', 'H44.132', 'M35.2', 'D86.9', 'D86.2', 'D86.0', 'B02.34', 'H15.003', 'H15.013', 'M45.A1', 'M45.A2', 'M45.A3']\n",
      "Covered Drug Codes: ['2640849', '2641642', '2103477', '2640402', '2677776']\n",
      "Chunk ID: 001_3\n",
      "Search Score: 0.02321603149175644\n",
      "Reranker Score: 1.7773933410644531\n",
      "--------------------------------------------------------------------------------\n",
      "Document Metadata:\n",
      "Parent ID: 001\n",
      "Parent Path: https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/001.pdf\n",
      "Policy Name: Inflammatory Conditions - Adalimumab Products Prior Authorization Policy\n",
      "Payer Name: Cigna\n",
      "Drug Names: ['Abrilada (adalimumab-afzb)', 'adalimumab-aacf', 'adalimumab-adaz', 'adalimumab-adbm', 'adalimumab-fkjp', 'adalimumab-ryvk', 'Humira (adalimumab)', 'Amjevita (adalimumab-atto)', 'Cyltezo (adalimumab-adbm)', 'Hadlima (adalimumab-bwwd)', 'Hulio (adalimumab-fkjp)', 'Hyrimoz (adalimumab-adaz)', 'Idacio (adalimumab-aacf)', 'Simlandi (adalimumab-ryvk)', 'Yuflyma (adalimumab-aaty)', 'Yusimry (adalimumab-aqvh)']\n",
      "Medical Specialties: ['Rheumatology', 'Gastroenterology', 'Dermatology', 'Ophthalmology']\n",
      "Covered Diseases: ['Ankylosing spondylitis', \"Crohn's disease\", 'Hidradenitis suppurativa', 'Juvenile idiopathic arthritis', 'Plaque psoriasis', 'Psoriatic arthritis', 'Rheumatoid arthritis', 'Ulcerative colitis', 'Uveitis', \"Behcet's disease\", 'Pyoderma gangrenosum', 'Sarcoidosis', 'Scleritis', 'Axial spondyloarthritis']\n",
      "Covered Diseases ICD Codes: ['M08.1', 'M45.6', 'M45.2', 'K50.90', 'K50.913', 'K50.914', 'L73.2', 'L40.52', 'M06.9', 'M05.9', 'M06.08', 'K51.80', 'K51.813', 'K51.814', 'H44.133', 'H44.131', 'H44.132', 'M35.2', 'D86.9', 'D86.2', 'D86.0', 'B02.34', 'H15.003', 'H15.013', 'M45.A1', 'M45.A2', 'M45.A3']\n",
      "Covered Drug Codes: ['2640849', '2641642', '2103477', '2640402', '2677776']\n",
      "Chunk ID: 001_0\n",
      "Search Score: 0.022031962871551514\n",
      "Reranker Score: 1.7660503387451172\n",
      "--------------------------------------------------------------------------------\n",
      "Document Metadata:\n",
      "Parent ID: 001\n",
      "Parent Path: https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/001.pdf\n",
      "Policy Name: Inflammatory Conditions - Adalimumab Products Prior Authorization Policy\n",
      "Payer Name: Cigna\n",
      "Drug Names: ['Abrilada (adalimumab-afzb)', 'adalimumab-aacf', 'adalimumab-adaz', 'adalimumab-adbm', 'adalimumab-fkjp', 'adalimumab-ryvk', 'Humira (adalimumab)', 'Amjevita (adalimumab-atto)', 'Cyltezo (adalimumab-adbm)', 'Hadlima (adalimumab-bwwd)', 'Hulio (adalimumab-fkjp)', 'Hyrimoz (adalimumab-adaz)', 'Idacio (adalimumab-aacf)', 'Simlandi (adalimumab-ryvk)', 'Yuflyma (adalimumab-aaty)', 'Yusimry (adalimumab-aqvh)']\n",
      "Medical Specialties: ['Rheumatology', 'Gastroenterology', 'Dermatology', 'Ophthalmology']\n",
      "Covered Diseases: ['Ankylosing spondylitis', \"Crohn's disease\", 'Hidradenitis suppurativa', 'Juvenile idiopathic arthritis', 'Plaque psoriasis', 'Psoriatic arthritis', 'Rheumatoid arthritis', 'Ulcerative colitis', 'Uveitis', \"Behcet's disease\", 'Pyoderma gangrenosum', 'Sarcoidosis', 'Scleritis', 'Axial spondyloarthritis']\n",
      "Covered Diseases ICD Codes: ['M08.1', 'M45.6', 'M45.2', 'K50.90', 'K50.913', 'K50.914', 'L73.2', 'L40.52', 'M06.9', 'M05.9', 'M06.08', 'K51.80', 'K51.813', 'K51.814', 'H44.133', 'H44.131', 'H44.132', 'M35.2', 'D86.9', 'D86.2', 'D86.0', 'B02.34', 'H15.003', 'H15.013', 'M45.A1', 'M45.A2', 'M45.A3']\n",
      "Covered Drug Codes: ['2640849', '2641642', '2103477', '2640402', '2677776']\n",
      "Chunk ID: 001_7\n",
      "Search Score: 0.024205941706895828\n",
      "Reranker Score: 1.6873582601547241\n",
      "--------------------------------------------------------------------------------\n"
     ]
    }
   ],
   "source": [
    "# Hybrid retrieval + rerank\n",
    "r = search_client.search(\n",
    "    search_text=search_query,\n",
    "    top=5,\n",
    "    vector_queries=[\n",
    "        VectorizedQuery(vector=embedding.data[0].embedding, k_nearest_neighbors=50, fields=\"vector\", weight=0.5),\n",
    "    ],\n",
    "    query_type=QueryType.SEMANTIC,\n",
    "    semantic_configuration_name=\"policy-index-semantic-config\",\n",
    "    query_language=\"en-us\",\n",
    "    query_caption=QueryCaptionType.EXTRACTIVE,\n",
    "    query_answer=QueryAnswerType.EXTRACTIVE,\n",
    ")\n",
    "\n",
    "# Iterate through the search results and print all metadata\n",
    "for doc in r:\n",
    "    print(\"Document Metadata:\")\n",
    "    print(f\"Parent ID: {doc.get('parent_id', 'N/A')}\")\n",
    "    print(f\"Parent Path: {doc.get('parent_path', 'N/A')}\")\n",
    "    print(f\"Policy Name: {doc.get('policy_name', 'N/A')}\")\n",
    "    print(f\"Payer Name: {doc.get('payer_name', 'N/A')}\")\n",
    "    print(f\"Drug Names: {doc.get('drug_names', 'N/A')}\")\n",
    "    print(f\"Medical Specialties: {doc.get('medical_specialties', 'N/A')}\")\n",
    "    print(f\"Covered Diseases: {doc.get('covered_diseases', 'N/A')}\")\n",
    "    print(f\"Covered Diseases ICD Codes: {doc.get('covered_diseases_icd_codes', 'N/A')}\")\n",
    "    print(f\"Covered Drug Codes: {doc.get('covered_drug_codes', 'N/A')}\")\n",
    "    print(f\"Chunk ID: {doc.get('chunk_id', 'N/A')}\")\n",
    "    print(f\"Search Score: {doc.get('@search.score', 'N/A')}\")\n",
    "    print(f\"Reranker Score: {doc.get('@search.reranker_score', 'N/A')}\")\n",
    "    print(\"-\" * 80)  # Separator for readability"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## **Filtering by Payer Name and ICD-10 Code**"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "The filter expression in the search query is used to narrow down the results based on specific conditions:\n",
    "\n",
    "1. **`payer_name eq 'Cigna'`**  \n",
    "   - This condition filters documents where the `payer_name` field is exactly `'Cigna'`.  \n",
    "   - It ensures that only documents related to the payer `'Cigna'` are included in the search results.\n",
    "\n",
    "2. **`covered_diseases_icd_codes/any(c: c eq 'M45.6')`**  \n",
    "   - This condition filters documents where the `covered_diseases_icd_codes` collection contains the value `'M45.6'`.  \n",
    "   - The `any()` function is used to check if any element in the `covered_diseases_icd_codes` array matches the specified value.  \n",
    "   - In this case, it ensures that only documents related to the ICD code `'M45.6'` (e.g., Ankylosing Spondylitis) are included.\n",
    "\n",
    "3. **Combining Conditions with `and`**  \n",
    "   - The `and` operator combines the two conditions, so the filter only returns documents where **both conditions are true**.  \n",
    "   - This means the results will include documents where the payer is `'Cigna'` **and** the ICD code `'M45.6'` is present in the `covered_diseases_icd_codes` field.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ID: 001, Policy Name: Inflammatory Conditions - Adalimumab Products Prior Authorization Policy, Payer Name: Cigna, Drug Names: ['Abrilada (adalimumab-afzb)', 'adalimumab-aacf', 'adalimumab-adaz', 'adalimumab-adbm', 'adalimumab-fkjp', 'adalimumab-ryvk', 'Humira (adalimumab)', 'Amjevita (adalimumab-atto)', 'Cyltezo (adalimumab-adbm)', 'Hadlima (adalimumab-bwwd)', 'Hulio (adalimumab-fkjp)', 'Hyrimoz (adalimumab-adaz)', 'Idacio (adalimumab-aacf)', 'Simlandi (adalimumab-ryvk)', 'Yuflyma (adalimumab-aaty)', 'Yusimry (adalimumab-aqvh)'], Medical Specialties: ['Rheumatology', 'Gastroenterology', 'Dermatology', 'Ophthalmology'], Covered Diseases: ['Ankylosing spondylitis', \"Crohn's disease\", 'Hidradenitis suppurativa', 'Juvenile idiopathic arthritis', 'Plaque psoriasis', 'Psoriatic arthritis', 'Rheumatoid arthritis', 'Ulcerative colitis', 'Uveitis', \"Behcet's disease\", 'Pyoderma gangrenosum', 'Sarcoidosis', 'Scleritis', 'Axial spondyloarthritis'], Score: 0.02182539738714695, Reranker Score: 1.8360580205917358. Content: \n",
      "ID: 001, Policy Name: Inflammatory Conditions - Adalimumab Products Prior Authorization Policy, Payer Name: Cigna, Drug Names: ['Abrilada (adalimumab-afzb)', 'adalimumab-aacf', 'adalimumab-adaz', 'adalimumab-adbm', 'adalimumab-fkjp', 'adalimumab-ryvk', 'Humira (adalimumab)', 'Amjevita (adalimumab-atto)', 'Cyltezo (adalimumab-adbm)', 'Hadlima (adalimumab-bwwd)', 'Hulio (adalimumab-fkjp)', 'Hyrimoz (adalimumab-adaz)', 'Idacio (adalimumab-aacf)', 'Simlandi (adalimumab-ryvk)', 'Yuflyma (adalimumab-aaty)', 'Yusimry (adalimumab-aqvh)'], Medical Specialties: ['Rheumatology', 'Gastroenterology', 'Dermatology', 'Ophthalmology'], Covered Diseases: ['Ankylosing spondylitis', \"Crohn's disease\", 'Hidradenitis suppurativa', 'Juvenile idiopathic arthritis', 'Plaque psoriasis', 'Psoriatic arthritis', 'Rheumatoid arthritis', 'Ulcerative colitis', 'Uveitis', \"Behcet's disease\", 'Pyoderma gangrenosum', 'Sarcoidosis', 'Scleritis', 'Axial spondyloarthritis'], Score: 0.022482436150312424, Reranker Score: 1.8358807563781738. Content: \n",
      "ID: 001, Policy Name: Inflammatory Conditions - Adalimumab Products Prior Authorization Policy, Payer Name: Cigna, Drug Names: ['Abrilada (adalimumab-afzb)', 'adalimumab-aacf', 'adalimumab-adaz', 'adalimumab-adbm', 'adalimumab-fkjp', 'adalimumab-ryvk', 'Humira (adalimumab)', 'Amjevita (adalimumab-atto)', 'Cyltezo (adalimumab-adbm)', 'Hadlima (adalimumab-bwwd)', 'Hulio (adalimumab-fkjp)', 'Hyrimoz (adalimumab-adaz)', 'Idacio (adalimumab-aacf)', 'Simlandi (adalimumab-ryvk)', 'Yuflyma (adalimumab-aaty)', 'Yusimry (adalimumab-aqvh)'], Medical Specialties: ['Rheumatology', 'Gastroenterology', 'Dermatology', 'Ophthalmology'], Covered Diseases: ['Ankylosing spondylitis', \"Crohn's disease\", 'Hidradenitis suppurativa', 'Juvenile idiopathic arthritis', 'Plaque psoriasis', 'Psoriatic arthritis', 'Rheumatoid arthritis', 'Ulcerative colitis', 'Uveitis', \"Behcet's disease\", 'Pyoderma gangrenosum', 'Sarcoidosis', 'Scleritis', 'Axial spondyloarthritis'], Score: 0.02321603149175644, Reranker Score: 1.7773933410644531. Content: \n",
      "ID: 001, Policy Name: Inflammatory Conditions - Adalimumab Products Prior Authorization Policy, Payer Name: Cigna, Drug Names: ['Abrilada (adalimumab-afzb)', 'adalimumab-aacf', 'adalimumab-adaz', 'adalimumab-adbm', 'adalimumab-fkjp', 'adalimumab-ryvk', 'Humira (adalimumab)', 'Amjevita (adalimumab-atto)', 'Cyltezo (adalimumab-adbm)', 'Hadlima (adalimumab-bwwd)', 'Hulio (adalimumab-fkjp)', 'Hyrimoz (adalimumab-adaz)', 'Idacio (adalimumab-aacf)', 'Simlandi (adalimumab-ryvk)', 'Yuflyma (adalimumab-aaty)', 'Yusimry (adalimumab-aqvh)'], Medical Specialties: ['Rheumatology', 'Gastroenterology', 'Dermatology', 'Ophthalmology'], Covered Diseases: ['Ankylosing spondylitis', \"Crohn's disease\", 'Hidradenitis suppurativa', 'Juvenile idiopathic arthritis', 'Plaque psoriasis', 'Psoriatic arthritis', 'Rheumatoid arthritis', 'Ulcerative colitis', 'Uveitis', \"Behcet's disease\", 'Pyoderma gangrenosum', 'Sarcoidosis', 'Scleritis', 'Axial spondyloarthritis'], Score: 0.022031962871551514, Reranker Score: 1.7660503387451172. Content: \n",
      "ID: 001, Policy Name: Inflammatory Conditions - Adalimumab Products Prior Authorization Policy, Payer Name: Cigna, Drug Names: ['Abrilada (adalimumab-afzb)', 'adalimumab-aacf', 'adalimumab-adaz', 'adalimumab-adbm', 'adalimumab-fkjp', 'adalimumab-ryvk', 'Humira (adalimumab)', 'Amjevita (adalimumab-atto)', 'Cyltezo (adalimumab-adbm)', 'Hadlima (adalimumab-bwwd)', 'Hulio (adalimumab-fkjp)', 'Hyrimoz (adalimumab-adaz)', 'Idacio (adalimumab-aacf)', 'Simlandi (adalimumab-ryvk)', 'Yuflyma (adalimumab-aaty)', 'Yusimry (adalimumab-aqvh)'], Medical Specialties: ['Rheumatology', 'Gastroenterology', 'Dermatology', 'Ophthalmology'], Covered Diseases: ['Ankylosing spondylitis', \"Crohn's disease\", 'Hidradenitis suppurativa', 'Juvenile idiopathic arthritis', 'Plaque psoriasis', 'Psoriatic arthritis', 'Rheumatoid arthritis', 'Ulcerative colitis', 'Uveitis', \"Behcet's disease\", 'Pyoderma gangrenosum', 'Sarcoidosis', 'Scleritis', 'Axial spondyloarthritis'], Score: 0.024205941706895828, Reranker Score: 1.6873582601547241. Content: \n"
     ]
    }
   ],
   "source": [
    "# Perform the search query with the updated filter\n",
    "# Hybrid retrieval + rerank\n",
    "r = search_client.search(\n",
    "    search_text=search_query,\n",
    "    top=5,\n",
    "    vector_queries=[\n",
    "        VectorizedQuery(vector=embedding.data[0].embedding, k_nearest_neighbors=50, fields=\"vector\", weight=0.5),\n",
    "    ],\n",
    "    query_type=QueryType.SEMANTIC,\n",
    "    semantic_configuration_name=\"policy-index-semantic-config\",\n",
    "    query_language=\"en-us\",\n",
    "    query_caption=QueryCaptionType.EXTRACTIVE,\n",
    "    query_answer=QueryAnswerType.EXTRACTIVE,\n",
    "    filter=\"payer_name eq 'Cigna' and covered_diseases_icd_codes/any(c: c eq 'M45.6')\",  # Filter by payer name and ICD code\n",
    ")\n",
    "\n",
    "# Iterate through the search results and print all relevant metadata\n",
    "for doc in r:\n",
    "    content = doc.get(\"content\", \"\").replace(\"\\n\", \" \")[:1000]  # Limit content to 1000 characters for readability\n",
    "    print(\n",
    "        f\"ID: {doc.get('parent_id', 'N/A')}, \"\n",
    "        f\"Policy Name: {doc.get('policy_name', 'N/A')}, \"\n",
    "        f\"Payer Name: {doc.get('payer_name', 'N/A')}, \"\n",
    "        f\"Drug Names: {doc.get('drug_names', 'N/A')}, \"\n",
    "        f\"Medical Specialties: {doc.get('medical_specialties', 'N/A')}, \"\n",
    "        f\"Covered Diseases: {doc.get('covered_diseases', 'N/A')}, \"\n",
    "        f\"Score: {doc.get('@search.score', 'N/A')}, \"\n",
    "        f\"Reranker Score: {doc.get('@search.reranker_score', 'N/A')}. \"\n",
    "        f\"Content: {content}\"\n",
    "    )"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "mediindexer",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.16"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
